- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05675410
- Originalversuch
Eine Studie zum Vergleich der Standardtherapie zur Behandlung des Hodgkin-Lymphoms mit der Verwendung von zwei Medikamenten, Brentuximab Vedotin und Nivolumab
Eine randomisierte Phase-3-Interims-Response-adaptierte Studie zum Vergleich einer Standardtherapie mit einer immunonkologischen Therapie für Kinder und Erwachsene mit neu diagnostiziertem klassischem Hodgkin-Lymphom im Stadium I und II
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 positive lymphoma cells in a targeted way and delivers vedotin to kill them. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs such as doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine, and procarbazine hydrochloride work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Adding immunotherapy to the standard treatment of chemotherapy with or without radiation may increase survival and/or fewer short-term or long-term side effects in patients with classical Hodgkin lymphoma compared to the standard treatment alone.
Studienübersicht
Status
Intervention / Behandlung
- Arzneimittel: Cyclophosphamide
- Arzneimittel: Doxorubicin Hydrochloride
- Arzneimittel: Prednisone
- Verfahren: Biospecimen Collection
- Arzneimittel: Vincristine Sulfate
- Sonstiges: Questionnaire Administration
- Arzneimittel: Brentuximab Vedotin
- Biologisch: Nivolumab
- Arzneimittel: Etoposide
- Arzneimittel: Etoposide Phosphate
- Arzneimittel: Prednisolone
- Arzneimittel: Dacarbazine
- Arzneimittel: Vinblastine Sulfate
- Biologisch: Bleomycin Sulfate
- Verfahren: Computed Tomography
- Sonstiges: Fludeoxyglucose F-18
- Verfahren: Magnetic Resonance Imaging
- Verfahren: Positron Emission Tomography
- Strahlung: Involved-site Radiation Therapy
- Arzneimittel: Procarbazine Hydrochloride
Detaillierte Beschreibung
PRIMARY OBJECTIVES:
I. To compare the progression-free survival (PFS) of a standard chemotherapy approach versus an immunotherapy (IO) approach (brentuximab vedotin and nivolumab) in patients with newly diagnosed early stage classic Hodgkin lymphoma (cHL) who have a rapid early response (RER) as determined by position emission tomography post cycle 2 (PET2) after 2 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy.
II. To compare the PFS of a standard chemotherapy approach versus an IO therapy approach (brentuximab vedotin and nivolumab) plus involved site radiation therapy (ISRT) in patients with newly diagnosed early stage cHL who have a slow early response (SER) as determined by PET2 after 2 cycles of ABVD chemotherapy.
SECONDARY OBJECTIVES:
I. To demonstrate non-inferiority of overall survival (OS) at 12 years of IO therapy versus standard therapy in early stage cHL patients who have a RER as determined by PET2 after 2 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy.
II. To evaluate the overall survival (OS) at 12 years of IO therapy versus standard therapy in early stage cHL patients who have a SER as determined by PET2 after 2 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy.
III. To demonstrate non-inferiority of overall survival (OS) at 12 years of IO therapy versus standard therapy in early stage cHL patients.
IV. To evaluate in patients with newly diagnosed early stage cHL the PFS of a standard chemotherapy approach versus an IO therapy approach (brentuximab vedotin and nivolumab) in the overall cohort, in the favorable risk cohort, and in the unfavorable risk cohort.
V. To evaluate the event-free survival (EFS) at 12 years of patients undergoing standard chemotherapy versus an IO therapy approach (brentuximab vedotin and nivolumab).
VI. To compare the physician-reported treatment-related adverse event (AE) rates between a standard chemotherapy approach and an IO therapy approach (brentuximab vedotin and nivolumab) in patients with newly diagnosed early stage cHL.
VII. To compare patient-reported adverse events using pediatric and adult versions of Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), stratified by age groups, therapeutic arms, and receipt of radiation therapy (RT) over time.
VIII. To evaluate changes in patient-reported fatigue, cognitive functioning, and health-related quality of life (HRQoL), e.g., emotional, physical, and role functioning, by treatment arm, using validated adult and pediatric measurement systems.
IX. To evaluate self-reported late morbidities (e.g., cardiovascular, pulmonary and endocrine) over time for children, adolescents and adults undergoing standard chemotherapy versus an IO therapy approach (brentuximab vedotin and nivolumab) with and without RT using measures from the St. Jude Lifetime Cohort Study (SJLIFE).
X. To evaluate fludeoxyglucose F-18 (FDG)-position emission tomography (PET) measurements of metabolic tumor burden (MTV and total lesion glycolysis [TLG]) at PET at baseline (PET1) as a predictive marker of PFS.
XI. To evaluate the associations between race/ethnicity and key outcomes including early response to therapy, PFS and OS.
EXPLORATORY OBJECTIVES:
I. To evaluate the PFS of a standard chemotherapy approach versus an IO therapy approach (brentuximab vedotin and nivolumab) in patients with newly diagnosed early stage cHL across different age groups (ages 5-11 years, 12-21 years, 22-39 years, 40-60 years).
II. To bank specimens for future correlative studies. III. To assess concordance and discordance of rapid central review and local institutional review of FDG PET 5-point score (5-PS; previously referred to as Deauville score) at baseline PET1, interim PET2 and end of systemic therapy PET-end of systemic therapy (EST) SER.
IV. To assess the association between PFS and the quantitative FDG-PET/computed tomography (CT) parameters (PET MTV, TLG, delta-standardized uptake value [SUV] and PET SUV-based quantitative surrogates [qPET] of visual qualitative 5-PS) on measurements by automated measurements using convolutional neural networks (CNNs) through artificial-intelligence (AI) machine learning in the entire population.
V. To assess the agreement between quantitative FDG-PET/CT parameters obtained using AI and those based on measurements by a trained imaging physician.
VI. To compare patient-reported adverse events (via pediatric [Ped]-PRO-CTCAE and PRO-CTCAE) to provider adverse event reporting.
VII. To evaluate the association between self-reported race/ethnicity and social determinants of health.
VIII. To evaluate the associations between race/ethnicity and post-progression/post-relapse overall survival.
IX. To evaluate the completion rates of PRO and health-related quality of life (HRQoL) contact forms at 1 year off treatment for the first 450 eligible patients.
X. To collect contact information from participants for future re-contact.
OUTLINE: Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride intravenously [IV] over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or magnetic resonance imaging (MRI) and are identified as RER or SER.
Patients with a favorable risk status and RER are randomized to Arm A or Arm B. Patients with a favorable risk status and SER are randomized to Arm C or Arm D. Patients with an unfavorable risk status and RER are randomized to Arm E or Arm F. Patients with an unfavorable risk status and SER are randomized to Arm G or Arm H.
ARM A (RER, FAVORABLE): Patients receive ABVD IV for an additional 2 cycles on study. Each cycle lasts 28 days and ABVD is administered on days 1 and 15 of each cycle in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.
ARM B (RER, FAVORABLE): Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30 minutes once during each treatment cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.
ARM C (SER, FAVORABLE): Patients receive either the eBEACOPP regimen (doxorubicin hydrochloride IV over 3-15 minutes on day 1, cyclophosphamide IV over 30-60 minutes on day 1, etoposide or etoposide phosphate IV over 2-4 hours on days 1-3, prednisone or prednisolone orally [PO] twice daily [BID] on days 1-14, procarbazine hydrochloride PO on days 1-7, bleomycin sulfate IV over at least 10 minutes on day 8, and vincristine sulfate IV on day 8 of each cycle) or the eBPDac regimen (doxorubicin hydrochloride IV 3-15 minutes on day 1, cyclophosphamide IV 30-60 minutes on day 1, etoposide or etoposide phosphate IV over 2-4 hours on days 1-3, prednisone or prednisolone PO BID on days 1-14, dacarbazine IV over 15-60 minutes on days 2 & 3, bleomycin sulfate IV over at least 10 minutes on day 4, 5, 6, 7, or 8, vincristine sulfate IV on day 4, 5, 6, 7, or 8 of each cycle). Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Subsequently, patients undergo ISRT. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.
ARM D (SER, FAVORABLE): Patients receive brentuximab vedotin IV and nivolumab IV as in arm B followed by ISRT. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.
ARM E (RER, UNFAVORABLE): Patients receive AVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, vinblastine IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.
ARM F (RER, UNFAVORABLE): Patients receive treatment as in arm B. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.
ARM G (SER, UNFAVORABLE): Patients receive treatment and imaging, and may undergo blood sample collection as in arm C.
ARM H (SER, UNFAVORABLE): Patients receive treatment and imaging, and may undergo blood sample collection as in arm D.
After completion of study treatment, patients are followed up every 3 months for the first year, then every 6 months for the second and third year, then annually until 12 years from date of registration.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
-
Québec, Kanada, G1V 4G2
- Rekrutierung
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
Hauptermittler:
- Bruno Michon
-
Kontakt:
- Site Public Contact
- Telefonnummer: 418-525-4444
- E-Mail: rechclinique@crchudequebec.ulaval.ca
-
-
Alberta
-
Calgary, Alberta, Kanada, T3B 6A8
- Rekrutierung
- Alberta Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 403-220-6898
- E-Mail: research4kids@ucalgary.ca
-
Hauptermittler:
- Victor A. Lewis
-
Edmonton, Alberta, Kanada, T6G 2B7
- Rekrutierung
- University of Alberta Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 780-407-8798
- E-Mail: pedsoncologyresearch@ahs.ca
-
Hauptermittler:
- Sarah J. McKillop
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V6H 3V4
- Rekrutierung
- British Columbia Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 6477 604-875-2345
-
Hauptermittler:
- Rebecca J. Deyell
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R3E 0V9
- Rekrutierung
- CancerCare Manitoba
-
Kontakt:
- Site Public Contact
- Telefonnummer: 866-561-1026
- E-Mail: ctu_web@cancercare.mb.ca
-
Hauptermittler:
- Stephanie M. Villeneuve
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3K 6R8
- Rekrutierung
- IWK Health Centre
-
Kontakt:
- Site Public Contact
- Telefonnummer: 902-470-8520
- E-Mail: Research@iwk.nshealth.ca
-
Hauptermittler:
- Chelsea Ash
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8N 3Z5
- Rekrutierung
- McMaster Children's Hospital at Hamilton Health Sciences
-
Kontakt:
- Site Public Contact
- Telefonnummer: 905-521-2100
-
Hauptermittler:
- Uma H. Athale
-
London, Ontario, Kanada, N6A 5W9
- Rekrutierung
- Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 519-685-8306
-
Hauptermittler:
- Shayna M. Zelcer
-
Ottawa, Ontario, Kanada, K1H 8L1
- Rekrutierung
- Children's Hospital of Eastern Ontario
-
Kontakt:
- Site Public Contact
- Telefonnummer: 613-737-7600
-
Hauptermittler:
- Donna L. Johnston
-
Toronto, Ontario, Kanada, M5G 1X8
- Rekrutierung
- Hospital for Sick Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 416-813-7654
- E-Mail: ask.CRS@sickkids.ca
-
Hauptermittler:
- Angela S. Punnett
-
-
Quebec
-
Montreal, Quebec, Kanada, H3H 1P3
- Rekrutierung
- The Montreal Children's Hospital of the MUHC
-
Kontakt:
- Site Public Contact
- Telefonnummer: 514-412-4445
- E-Mail: info@thechildren.com
-
Hauptermittler:
- Stephanie Mourad
-
Montreal, Quebec, Kanada, H3T 1C5
- Rekrutierung
- Centre Hospitalier Universitaire Sainte-Justine
-
Hauptermittler:
- Monia Marzouki
-
Kontakt:
- Site Public Contact
- Telefonnummer: 514-345-4931
- E-Mail: yvan.samson@umontreal.ca
-
Sherbrooke, Quebec, Kanada, J1H 5N4
- Rekrutierung
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
Kontakt:
- Site Public Contact
- Telefonnummer: 819-820-6480
- E-Mail: crcinformation.chus@ssss.gouv.qc.ca
-
Hauptermittler:
- Stephanie Vairy
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Kanada, S7N 0W8
- Rekrutierung
- Jim Pattison Children's Hospital
-
Hauptermittler:
- Kathleen Felton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 306-655-3544
- E-Mail: Jessica.Marien@saskhealthauthority.ca
-
-
-
-
-
San Juan, Puerto Rico, 00926
- Rekrutierung
- University Pediatric Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 787-474-0333
-
Hauptermittler:
- Maria E. Echevarria
-
-
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35233
- Rekrutierung
- Children's Hospital of Alabama
-
Hauptermittler:
- Ana C. Xavier
-
Kontakt:
- Site Public Contact
- Telefonnummer: 205-638-9285
- E-Mail: oncologyresearch@peds.uab.edu
-
Mobile, Alabama, Vereinigte Staaten, 36604
- Rekrutierung
- USA Health Strada Patient Care Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-388-8721
-
Hauptermittler:
- Hamayun Imran
-
-
Alaska
-
Anchorage, Alaska, Vereinigte Staaten, 99508
- Rekrutierung
- Providence Alaska Medical Center
-
Hauptermittler:
- Dan S. Zuckerman
-
Kontakt:
- Site Public Contact
- Telefonnummer: 907-212-6871
- E-Mail: AKPAMC.OncologyResearchSupport@providence.org
-
-
Arizona
-
Goodyear, Arizona, Vereinigte Staaten, 85338
- Rekrutierung
- CTCA at Western Regional Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 623-207-3000
-
Hauptermittler:
- Sarah Monick
-
Mesa, Arizona, Vereinigte Staaten, 85202
- Rekrutierung
- Banner Children's at Desert
-
Kontakt:
- Site Public Contact
- Telefonnummer: 480-412-3100
-
Hauptermittler:
- Joseph C. Torkildson
-
Phoenix, Arizona, Vereinigte Staaten, 85016
- Rekrutierung
- Phoenix Childrens Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 602-546-0920
-
Hauptermittler:
- Alexandra M. Walsh
-
Phoenix, Arizona, Vereinigte Staaten, 85004
- Rekrutierung
- Cancer Center at Saint Joseph's
-
Hauptermittler:
- Loretta J. Nastoupil
-
Kontakt:
- Site Public Contact
- Telefonnummer: 720-874-1881
- E-Mail: ResearchInstituteInquiries@CommonSpirit.org
-
-
Arkansas
-
Little Rock, Arkansas, Vereinigte Staaten, 72202-3591
- Rekrutierung
- Arkansas Children's Hospital
-
Hauptermittler:
- Michael W. Bishop
-
Kontakt:
- Site Public Contact
- Telefonnummer: 501-364-7373
-
-
California
-
Carmichael, California, Vereinigte Staaten, 95608
- Rekrutierung
- Mercy San Juan Medical Center
-
Hauptermittler:
- Loretta J. Nastoupil
-
Kontakt:
- Site Public Contact
- Telefonnummer: 720-874-1881
- E-Mail: ResearchInstituteInquiries@commonspirit.org
-
Carmichael, California, Vereinigte Staaten, 95608
- Rekrutierung
- Mercy Cancer Center - Carmichael
-
Hauptermittler:
- Loretta J. Nastoupil
-
Kontakt:
- Site Public Contact
- Telefonnummer: 720-874-1881
- E-Mail: ResearchInstituteInquiries@CommonSpirit.org
-
Corona, California, Vereinigte Staaten, 92882
- Rekrutierung
- City of Hope Corona
-
Hauptermittler:
- Alex F. Herrera
-
Kontakt:
- Site Public Contact
- Telefonnummer: 626-256-4673
- E-Mail: becomingapatient@coh.org
-
Costa Mesa, California, Vereinigte Staaten, 92627
- Rekrutierung
- UC Irvine Health Cancer Center-Newport
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-827-8839
-
Hauptermittler:
- Nicole Foley
-
Downey, California, Vereinigte Staaten, 90242
- Rekrutierung
- Kaiser Permanente Downey Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 626-564-3455
-
Hauptermittler:
- Robert M. Cooper
-
Duarte, California, Vereinigte Staaten, 91010
- Rekrutierung
- City of Hope Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-826-4673
- E-Mail: becomingapatient@coh.org
-
Hauptermittler:
- Alex F. Herrera
-
Dublin, California, Vereinigte Staaten, 94568
- Rekrutierung
- Kaiser Permanente Dublin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
-
Hauptermittler:
- Sachdev P. Thomas
-
Elk Grove, California, Vereinigte Staaten, 95758
- Rekrutierung
- Mercy Cancer Center - Elk Grove
-
Hauptermittler:
- Loretta J. Nastoupil
-
Kontakt:
- Site Public Contact
- Telefonnummer: 720-874-1881
- E-Mail: ResearchInstituteInquiries@CommonSpirit.org
-
Fremont, California, Vereinigte Staaten, 94538
- Rekrutierung
- Kaiser Permanente-Fremont
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-Mail: Kpoct@kp.org
-
Hauptermittler:
- Sachdev P. Thomas
-
Fresno, California, Vereinigte Staaten, 93720
- Rekrutierung
- Kaiser Permanente-Fresno
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-Mail: Kpoct@kp.org
-
Hauptermittler:
- Sachdev P. Thomas
-
Fresno, California, Vereinigte Staaten, 93720
- Suspendiert
- Kaiser Permanente Fresno Orchard Plaza
-
Huntington Beach, California, Vereinigte Staaten, 92648
- Rekrutierung
- City of Hope Seacliff
-
Hauptermittler:
- Alex F. Herrera
-
Kontakt:
- Site Public Contact
- Telefonnummer: 626-256-4673
-
Irvine, California, Vereinigte Staaten, 92618
- Rekrutierung
- City of Hope at Irvine Lennar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-467-3411
-
Hauptermittler:
- Alex F. Herrera
-
Irvine, California, Vereinigte Staaten, 92612
- Rekrutierung
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-827-8839
- E-Mail: ucstudy@uci.edu
-
Hauptermittler:
- Nicole Foley
-
Lancaster, California, Vereinigte Staaten, 93534
- Rekrutierung
- City of Hope Antelope Valley
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-826-4673
- E-Mail: becomingapatient@coh.org
-
Hauptermittler:
- Alex F. Herrera
-
Loma Linda, California, Vereinigte Staaten, 92354
- Rekrutierung
- Loma Linda University Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 909-558-4050
-
Hauptermittler:
- Albert Kheradpour
-
Long Beach, California, Vereinigte Staaten, 90806
- Rekrutierung
- Miller Children's and Women's Hospital Long Beach
-
Kontakt:
- Site Public Contact
- Telefonnummer: 562-933-5600
-
Hauptermittler:
- Jacqueline N. Casillas
-
Long Beach, California, Vereinigte Staaten, 90813
- Rekrutierung
- City of Hope at Long Beach Elm
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-467-3411
-
Hauptermittler:
- Alex F. Herrera
-
Los Angeles, California, Vereinigte Staaten, 90027
- Rekrutierung
- Children's Hospital Los Angeles
-
Kontakt:
- Site Public Contact
- Telefonnummer: 323-361-4110
-
Hauptermittler:
- Andrew Doan
-
Los Angeles, California, Vereinigte Staaten, 90048
- Rekrutierung
- Cedars-Sinai Medical Center
-
Hauptermittler:
- Nicole M. Baca
-
Kontakt:
- Site Public Contact
- Telefonnummer: 310-423-2133
- E-Mail: Cancer.trial.info@cshs.org
-
Madera, California, Vereinigte Staaten, 93636
- Rekrutierung
- Valley Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 559-353-3000
- E-Mail: Research@valleychildrens.org
-
Hauptermittler:
- Ruetima Titapiwatanakun
-
Modesto, California, Vereinigte Staaten, 95356
- Rekrutierung
- Kaiser Permanente-Modesto
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-Mail: Kpoct@kp.org
-
Hauptermittler:
- Sachdev P. Thomas
-
Modesto, California, Vereinigte Staaten, 95356
- Suspendiert
- Kaiser Permanente- Modesto MOB II
-
Newport Beach, California, Vereinigte Staaten, 92660
- Rekrutierung
- City of Hope Newport Beach
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-467-3411
-
Hauptermittler:
- Alex F. Herrera
-
Oakland, California, Vereinigte Staaten, 94611
- Rekrutierung
- Kaiser Permanente-Oakland
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-Mail: Kpoct@kp.org
-
Hauptermittler:
- Aarati V. Rao
-
Orange, California, Vereinigte Staaten, 92868
- Rekrutierung
- Children's Hospital of Orange County
-
Kontakt:
- Site Public Contact
- Telefonnummer: 714-509-8646
- E-Mail: oncresearch@choc.org
-
Hauptermittler:
- Elyssa M. Rubin
-
Orange, California, Vereinigte Staaten, 92868
- Rekrutierung
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-827-8839
- E-Mail: ucstudy@uci.edu
-
Hauptermittler:
- Nicole Foley
-
Rocklin, California, Vereinigte Staaten, 95765
- Rekrutierung
- Mercy Cancer Center - Rocklin
-
Hauptermittler:
- Loretta J. Nastoupil
-
Kontakt:
- Site Public Contact
- Telefonnummer: 720-874-1881
- E-Mail: ResearchInstituteInquiries@CommonSpirit.org
-
Sacramento, California, Vereinigte Staaten, 95814
- Rekrutierung
- Kaiser Permanente Downtown Commons
-
Hauptermittler:
- Sachdev P. Thomas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-Mail: kpoct@kp.org
-
Sacramento, California, Vereinigte Staaten, 95816
- Rekrutierung
- Sutter Medical Center Sacramento
-
Kontakt:
- Site Public Contact
- E-Mail: clinicalresearch@sutterhealth.org
-
Hauptermittler:
- Sandra Baril
-
Sacramento, California, Vereinigte Staaten, 95823
- Rekrutierung
- Kaiser Permanente-South Sacramento
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-Mail: Kpoct@kp.org
-
Hauptermittler:
- Sachdev P. Thomas
-
Sacramento, California, Vereinigte Staaten, 95816
- Rekrutierung
- Mercy Cancer Center - Sacramento
-
Hauptermittler:
- Loretta J. Nastoupil
-
Kontakt:
- Site Public Contact
- Telefonnummer: 720-874-1881
- E-Mail: ResearchInstituteInquiries@CommonSpirit.org
-
San Diego, California, Vereinigte Staaten, 92123
- Rekrutierung
- Rady Children's Hospital - San Diego
-
Kontakt:
- Site Public Contact
- Telefonnummer: 858-966-5934
-
Hauptermittler:
- William D. Roberts
-
San Diego, California, Vereinigte Staaten, 92134
- Rekrutierung
- Naval Medical Center -San Diego
-
Kontakt:
- Site Public Contact
- Telefonnummer: 619-532-8712
-
Hauptermittler:
- Yoko T. Udaka
-
San Francisco, California, Vereinigte Staaten, 94115
- Rekrutierung
- Kaiser Permanente-San Francisco
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-Mail: Kpoct@kp.org
-
Hauptermittler:
- Sachdev P. Thomas
-
San Jose, California, Vereinigte Staaten, 95119
- Rekrutierung
- Kaiser Permanente-Santa Teresa-San Jose
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-Mail: Kpoct@kp.org
-
Hauptermittler:
- Sachdev P. Thomas
-
San Leandro, California, Vereinigte Staaten, 94577
- Rekrutierung
- Kaiser Permanente San Leandro
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-Mail: Kpoct@kp.org
-
Hauptermittler:
- Sachdev P. Thomas
-
San Rafael, California, Vereinigte Staaten, 94903
- Rekrutierung
- Kaiser San Rafael-Gallinas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-Mail: Kpoct@kp.org
-
Hauptermittler:
- Sachdev P. Thomas
-
Santa Barbara, California, Vereinigte Staaten, 93102
- Rekrutierung
- Santa Barbara Cottage Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 805-682-7300
-
Hauptermittler:
- Shivani Upadhyay
-
Santa Rosa, California, Vereinigte Staaten, 95403
- Rekrutierung
- Kaiser Permanente-Santa Rosa
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-Mail: Kpoct@kp.org
-
Hauptermittler:
- Sachdev P. Thomas
-
South Pasadena, California, Vereinigte Staaten, 91030
- Rekrutierung
- City of Hope South Pasadena
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-826-4673
- E-Mail: becomingapatient@coh.org
-
Hauptermittler:
- Alex F. Herrera
-
South San Francisco, California, Vereinigte Staaten, 94080
- Rekrutierung
- Kaiser Permanente-South San Francisco
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-Mail: Kpoct@kp.org
-
Hauptermittler:
- Sachdev P. Thomas
-
Torrance, California, Vereinigte Staaten, 90503
- Rekrutierung
- City of Hope South Bay
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-467-3411
-
Hauptermittler:
- Alex F. Herrera
-
Upland, California, Vereinigte Staaten, 91786
- Rekrutierung
- City of Hope Upland
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-826-4673
- E-Mail: becomingapatient@coh.org
-
Hauptermittler:
- Alex F. Herrera
-
Vallejo, California, Vereinigte Staaten, 94589
- Rekrutierung
- Kaiser Permanente-Vallejo
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-Mail: Kpoct@kp.org
-
Hauptermittler:
- Sachdev P. Thomas
-
Walnut Creek, California, Vereinigte Staaten, 94596
- Rekrutierung
- Kaiser Permanente-Walnut Creek
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-Mail: Kpoct@kp.org
-
Hauptermittler:
- Sachdev P. Thomas
-
Woodland, California, Vereinigte Staaten, 95695
- Rekrutierung
- Woodland Memorial Hospital
-
Hauptermittler:
- Loretta J. Nastoupil
-
Kontakt:
- Site Public Contact
- Telefonnummer: 720-874-1881
- E-Mail: ResearchInstituteInquiries@CommonSpirit.org
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80045
- Rekrutierung
- Children's Hospital Colorado
-
Kontakt:
- Site Public Contact
- Telefonnummer: 303-764-5056
- E-Mail: josh.b.gordon@nsmtp.kp.org
-
Hauptermittler:
- Kelly W. Maloney
-
Aurora, Colorado, Vereinigte Staaten, 80045
- Rekrutierung
- UCHealth University of Colorado Hospital
-
Hauptermittler:
- Sarah Milgrom
-
Kontakt:
- Site Public Contact
- Telefonnummer: 720-848-0650
-
Colorado Springs, Colorado, Vereinigte Staaten, 80909
- Rekrutierung
- UCHealth Memorial Hospital Central
-
Hauptermittler:
- Sarah Milgrom
-
Kontakt:
- Site Public Contact
- Telefonnummer: 719-365-2406
-
Colorado Springs, Colorado, Vereinigte Staaten, 80920
- Rekrutierung
- Memorial Hospital North
-
Hauptermittler:
- Sarah Milgrom
-
Kontakt:
- Site Public Contact
- Telefonnummer: 719-364-6700
-
Denver, Colorado, Vereinigte Staaten, 80218
- Rekrutierung
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 303-832-2344
- E-Mail: PSGResearchSharedMailbox@HCAHealthcare.com
-
Hauptermittler:
- Florence Choo
-
Fort Collins, Colorado, Vereinigte Staaten, 80524
- Rekrutierung
- Poudre Valley Hospital
-
Hauptermittler:
- Sarah Milgrom
-
Kontakt:
- Site Public Contact
- Telefonnummer: 970-297-6150
-
Fort Collins, Colorado, Vereinigte Staaten, 80528
- Rekrutierung
- Cancer Care and Hematology-Fort Collins
-
Hauptermittler:
- Sarah Milgrom
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-823-5923
- E-Mail: ctsucontact@westat.com
-
Greeley, Colorado, Vereinigte Staaten, 80631
- Rekrutierung
- UCHealth Greeley Hospital
-
Hauptermittler:
- Sarah Milgrom
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-823-5923
- E-Mail: ctsucontact@westat.com
-
Loveland, Colorado, Vereinigte Staaten, 80538
- Rekrutierung
- Medical Center of the Rockies
-
Hauptermittler:
- Sarah Milgrom
-
Kontakt:
- Site Public Contact
- Telefonnummer: 970-203-7083
-
-
Connecticut
-
Derby, Connecticut, Vereinigte Staaten, 06418
- Rekrutierung
- Smilow Cancer Hospital-Derby Care Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
Hauptermittler:
- Farzana Pashankar
-
Fairfield, Connecticut, Vereinigte Staaten, 06824
- Rekrutierung
- Smilow Cancer Hospital Care Center-Fairfield
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
Hauptermittler:
- Farzana Pashankar
-
Glastonbury, Connecticut, Vereinigte Staaten, 06033
- Rekrutierung
- Smilow Cancer Hospital Care Center at Glastonbury
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
Hauptermittler:
- Farzana Pashankar
-
Greenwich, Connecticut, Vereinigte Staaten, 06830
- Rekrutierung
- Smilow Cancer Hospital Care Center at Greenwich
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
Hauptermittler:
- Farzana Pashankar
-
Guilford, Connecticut, Vereinigte Staaten, 06437
- Rekrutierung
- Smilow Cancer Hospital Care Center - Guilford
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
Hauptermittler:
- Farzana Pashankar
-
Hartford, Connecticut, Vereinigte Staaten, 06106
- Rekrutierung
- Connecticut Children's Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 860-545-9981
-
Hauptermittler:
- Michael S. Isakoff
-
Hartford, Connecticut, Vereinigte Staaten, 06105
- Rekrutierung
- Smilow Cancer Hospital Care Center at Saint Francis
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
Hauptermittler:
- Farzana Pashankar
-
New Haven, Connecticut, Vereinigte Staaten, 06520
- Rekrutierung
- Yale University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
Hauptermittler:
- Farzana Pashankar
-
North Haven, Connecticut, Vereinigte Staaten, 06473
- Rekrutierung
- Yale-New Haven Hospital North Haven Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
Hauptermittler:
- Farzana Pashankar
-
Stamford, Connecticut, Vereinigte Staaten, 06902
- Rekrutierung
- Smilow Cancer Hospital Care Center at Long Ridge
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
Hauptermittler:
- Farzana Pashankar
-
Torrington, Connecticut, Vereinigte Staaten, 06790
- Rekrutierung
- Smilow Cancer Hospital-Torrington Care Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
Hauptermittler:
- Farzana Pashankar
-
Trumbull, Connecticut, Vereinigte Staaten, 06611
- Rekrutierung
- Smilow Cancer Hospital Care Center-Trumbull
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
Hauptermittler:
- Farzana Pashankar
-
Waterbury, Connecticut, Vereinigte Staaten, 06708
- Rekrutierung
- Smilow Cancer Hospital-Waterbury Care Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
Hauptermittler:
- Farzana Pashankar
-
Waterford, Connecticut, Vereinigte Staaten, 06385
- Rekrutierung
- Smilow Cancer Hospital Care Center - Waterford
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
Hauptermittler:
- Farzana Pashankar
-
-
Delaware
-
Wilmington, Delaware, Vereinigte Staaten, 19803
- Rekrutierung
- Alfred I duPont Hospital for Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 302-651-5572
- E-Mail: Allison.bruce@nemours.org
-
Hauptermittler:
- Vibhuti Agarwal
-
-
District of Columbia
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20010
- Rekrutierung
- Children's National Medical Center
-
Hauptermittler:
- Jeffrey S. Dome
-
Kontakt:
- Site Public Contact
- Telefonnummer: 202-476-2800
- E-Mail: OncCRC_OnCall@childrensnational.org
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20007
- Rekrutierung
- MedStar Georgetown University Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 202-444-2223
-
Hauptermittler:
- Caileigh Pudela
-
-
Florida
-
Fort Lauderdale, Florida, Vereinigte Staaten, 33316
- Rekrutierung
- Broward Health Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 302-651-5572
- E-Mail: Allison.bruce@nemours.org
-
Hauptermittler:
- Hector M. Rodriguez-Cortes
-
Fort Myers, Florida, Vereinigte Staaten, 33908
- Rekrutierung
- Golisano Children's Hospital of Southwest Florida
-
Kontakt:
- Site Public Contact
- Telefonnummer: 239-343-5333
- E-Mail: molly.arnstrom@leehealth.org
-
Hauptermittler:
- Emad K. Salman
-
Gainesville, Florida, Vereinigte Staaten, 32610
- Rekrutierung
- UF Health Cancer Institute - Gainesville
-
Hauptermittler:
- Brian Stover
-
Kontakt:
- Site Public Contact
- Telefonnummer: 352-273-8010
-
Hollywood, Florida, Vereinigte Staaten, 33021
- Rekrutierung
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 954-265-1847
- E-Mail: OHR@mhs.net
-
Hauptermittler:
- Iftikhar Hanif
-
Jacksonville, Florida, Vereinigte Staaten, 32207
- Rekrutierung
- Nemours Children's Clinic-Jacksonville
-
Kontakt:
- Site Public Contact
- Telefonnummer: 302-651-5572
- E-Mail: Allison.bruce@nemours.org
-
Hauptermittler:
- Vibhuti Agarwal
-
Jacksonville, Florida, Vereinigte Staaten, 32224-9980
- Rekrutierung
- Mayo Clinic in Florida
-
Hauptermittler:
- Mira Kohorst
-
Kontakt:
- Site Public Contact
- Telefonnummer: 855-776-0015
-
Miami, Florida, Vereinigte Staaten, 33155
- Rekrutierung
- Nicklaus Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-624-2778
-
Hauptermittler:
- Ziad A. Khatib
-
Miami, Florida, Vereinigte Staaten, 33136
- Suspendiert
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami Beach, Florida, Vereinigte Staaten, 33140
- Rekrutierung
- Mount Sinai Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 305-674-2625
- E-Mail: Yvonne.Enriquez@msmc.com
-
Hauptermittler:
- Jacqueline C. Barrientos
-
Orlando, Florida, Vereinigte Staaten, 32806
- Rekrutierung
- Arnold Palmer Hospital for Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 321-841-5357
- E-Mail: Jennifer.spinelli@orlandohealth.com
-
Hauptermittler:
- Zhongbo Hu
-
Orlando, Florida, Vereinigte Staaten, 32827
- Rekrutierung
- Nemours Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 302-651-5572
- E-Mail: Allison.bruce@nemours.org
-
Hauptermittler:
- Vibhuti Agarwal
-
Orlando, Florida, Vereinigte Staaten, 32803
- Rekrutierung
- AdventHealth Orlando
-
Kontakt:
- Site Public Contact
- Telefonnummer: 407-303-2090
- E-Mail: FH.Cancer.Research@flhosp.org
-
Hauptermittler:
- Fouad M. Hajjar
-
Pensacola, Florida, Vereinigte Staaten, 32504
- Suspendiert
- Sacred Heart Hospital
-
Pensacola, Florida, Vereinigte Staaten, 32504
- Rekrutierung
- Nemours Children's Clinic - Pensacola
-
Kontakt:
- Site Public Contact
- E-Mail: helpdesk@childrensoncologygroup.org
-
Hauptermittler:
- Jeffrey H. Schwartz
-
St. Petersburg, Florida, Vereinigte Staaten, 33701
- Rekrutierung
- Johns Hopkins All Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 727-767-4784
- E-Mail: Ashley.Repp@jhmi.edu
-
Hauptermittler:
- Jennifer B. Dean
-
Tampa, Florida, Vereinigte Staaten, 33606
- Rekrutierung
- Tampa General Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 813-844-7829
- E-Mail: syapchanyk@tgh.org
-
Hauptermittler:
- Andrew J. Galligan
-
Tampa, Florida, Vereinigte Staaten, 33607
- Rekrutierung
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
Kontakt:
- Site Public Contact
- Telefonnummer: 813-357-0849
- E-Mail: jennifer.manns@baycare.org
-
Hauptermittler:
- Don E. Eslin
-
West Palm Beach, Florida, Vereinigte Staaten, 33407
- Rekrutierung
- Saint Mary's Medical Center
-
Hauptermittler:
- Matthew D. Ramirez
-
Kontakt:
- Site Public Contact
- Telefonnummer: 561-822-4745
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30322
- Rekrutierung
- Emory University Hospital/Winship Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 404-778-1868
-
Hauptermittler:
- Pamela B. Allen
-
Atlanta, Georgia, Vereinigte Staaten, 30303
- Rekrutierung
- Grady Health System
-
Kontakt:
- Site Public Contact
- Telefonnummer: 404-778-1868
-
Hauptermittler:
- Pamela B. Allen
-
Atlanta, Georgia, Vereinigte Staaten, 30308
- Rekrutierung
- Emory University Hospital Midtown
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-946-7447
-
Hauptermittler:
- Pamela B. Allen
-
Atlanta, Georgia, Vereinigte Staaten, 30342
- Rekrutierung
- Emory Saint Joseph's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 404-851-7115
-
Hauptermittler:
- Pamela B. Allen
-
Atlanta, Georgia, Vereinigte Staaten, 30308
- Rekrutierung
- Emory Proton Therapy Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 404-251-2854
- E-Mail: allyson.anderson@emory.edu
-
Hauptermittler:
- Pamela B. Allen
-
Atlanta, Georgia, Vereinigte Staaten, 30329
- Rekrutierung
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Hauptermittler:
- Diana Fridlyand
-
Kontakt:
- Site Public Contact
- Telefonnummer: 404-785-0232
- E-Mail: Olivia.Floyd@choa.org
-
Augusta, Georgia, Vereinigte Staaten, 30912
- Rekrutierung
- Augusta University Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 706-721-2388
- E-Mail: ga_cares@augusta.edu
-
Hauptermittler:
- Colleen H. McDonough
-
Macon, Georgia, Vereinigte Staaten, 31201
- Rekrutierung
- Atrium Health Navicent
-
Hauptermittler:
- Sushmita Nair
-
Kontakt:
- Site Public Contact
- Telefonnummer: 478-633-2152
- E-Mail: andrew.weatherall@atriumhealth.org
-
Savannah, Georgia, Vereinigte Staaten, 31404
- Rekrutierung
- Memorial Health University Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 912-350-7887
- E-Mail: Lorraine.OHara@hcahealthcare.com
-
Hauptermittler:
- James N. Yarnall
-
-
Hawaii
-
Honolulu, Hawaii, Vereinigte Staaten, 96826
- Rekrutierung
- Kapiolani Medical Center for Women and Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 808-983-6090
-
Hauptermittler:
- Wade T. Kyono
-
-
Idaho
-
Boise, Idaho, Vereinigte Staaten, 83712
- Rekrutierung
- Saint Luke's Cancer Institute - Boise
-
Hauptermittler:
- Martha M. Pacheco
-
Kontakt:
- Site Public Contact
- Telefonnummer: 208-381-2774
- E-Mail: eslinget@slhs.org
-
Boise, Idaho, Vereinigte Staaten, 83706
- Rekrutierung
- Saint Alphonsus Cancer Care Center-Boise
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-3671
- E-Mail: stephanie.couch@stjoeshealth.org
-
Hauptermittler:
- Christopher M. Reynolds
-
Caldwell, Idaho, Vereinigte Staaten, 83605
- Rekrutierung
- Saint Alphonsus Cancer Care Center-Caldwell
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-3671
- E-Mail: stephanie.couch@stjoeshealth.org
-
Hauptermittler:
- Christopher M. Reynolds
-
Fruitland, Idaho, Vereinigte Staaten, 83619
- Rekrutierung
- Saint Luke's Cancer Institute - Fruitland
-
Hauptermittler:
- Dan S. Zuckerman
-
Kontakt:
- Site Public Contact
- Telefonnummer: 208-381-2774
- E-Mail: eslinget@slhs.org
-
Meridian, Idaho, Vereinigte Staaten, 83642
- Rekrutierung
- Idaho Urologic Institute-Meridian
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-3671
- E-Mail: stephanie.couch@stjoeshealth.org
-
Hauptermittler:
- Christopher M. Reynolds
-
Meridian, Idaho, Vereinigte Staaten, 83642
- Rekrutierung
- Saint Luke's Cancer Institute - Meridian
-
Hauptermittler:
- Dan S. Zuckerman
-
Kontakt:
- Site Public Contact
- Telefonnummer: 208-381-2774
- E-Mail: eslinget@slhs.org
-
Nampa, Idaho, Vereinigte Staaten, 83687
- Rekrutierung
- Saint Luke's Cancer Institute - Nampa
-
Hauptermittler:
- Dan S. Zuckerman
-
Kontakt:
- Site Public Contact
- Telefonnummer: 208-381-2774
- E-Mail: eslinget@slhs.org
-
Nampa, Idaho, Vereinigte Staaten, 83687
- Rekrutierung
- Saint Alphonsus Cancer Care Center-Nampa
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Hauptermittler:
- Christopher M. Reynolds
-
Twin Falls, Idaho, Vereinigte Staaten, 83301
- Rekrutierung
- Saint Luke's Cancer Institute - Twin Falls
-
Hauptermittler:
- Dan S. Zuckerman
-
Kontakt:
- Site Public Contact
- Telefonnummer: 208-381-2774
- E-Mail: eslinget@slhs.org
-
-
Illinois
-
Aurora, Illinois, Vereinigte Staaten, 60504
- Rekrutierung
- Rush-Copley Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-978-6212
- E-Mail: RCMC_Cancer_Research@rush.edu
-
Hauptermittler:
- Joseph T. Meschi
-
Barrington, Illinois, Vereinigte Staaten, 60010
- Rekrutierung
- Advocate Good Shepherd Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-842-4847
-
Hauptermittler:
- Rebecca E. McFall
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Rekrutierung
- Lurie Children's Hospital-Chicago
-
Kontakt:
- Site Public Contact
- Telefonnummer: 773-880-4562
-
Hauptermittler:
- Joanna L. Weinstein
-
Chicago, Illinois, Vereinigte Staaten, 60637
- Rekrutierung
- University of Chicago Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 773-702-8222
- E-Mail: cancerclinicaltrials@bsd.uchicago.edu
-
Hauptermittler:
- Perry C. Morocco
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Rekrutierung
- Northwestern University
-
Hauptermittler:
- Jane N. Winter
-
Kontakt:
- Site Public Contact
- Telefonnummer: 312-695-1301
- E-Mail: cancer@northwestern.edu
-
Chicago, Illinois, Vereinigte Staaten, 60612
- Rekrutierung
- University of Illinois
-
Kontakt:
- Site Public Contact
- Telefonnummer: 312-355-3046
-
Hauptermittler:
- Dipti S. Dighe
-
Chicago, Illinois, Vereinigte Staaten, 60657
- Rekrutierung
- Advocate Illinois Masonic Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 773-296-5360
-
Hauptermittler:
- Rebecca E. McFall
-
Chicago, Illinois, Vereinigte Staaten, 60608
- Rekrutierung
- Mount Sinai Hospital Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 773-257-5960
- E-Mail: suhi@sinai.org
-
Hauptermittler:
- Pam G. Khosla
-
Chicago, Illinois, Vereinigte Staaten, 60625
- Rekrutierung
- Swedish Covenant Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 773-878-8200
-
Hauptermittler:
- Robert M. Eisner
-
Crystal Lake, Illinois, Vereinigte Staaten, 60014
- Rekrutierung
- AMG Crystal Lake - Oncology
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-929-6129
- E-Mail: advocateresearch@advocate.com
-
Hauptermittler:
- Rebecca E. McFall
-
Danville, Illinois, Vereinigte Staaten, 61832
- Rekrutierung
- Carle at The Riverfront
-
Hauptermittler:
- Priyank P. Patel
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-Mail: Research@Carle.com
-
DeKalb, Illinois, Vereinigte Staaten, 60115
- Rekrutierung
- Northwestern Medicine Cancer Center Kishwaukee
-
Hauptermittler:
- Jane N. Winter
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-352-5360
- E-Mail: Donald.Smith3@nm.org
-
Decatur, Illinois, Vereinigte Staaten, 62526
- Rekrutierung
- Decatur Memorial Hospital
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-Mail: morganthaler.jodi@mhsil.com
-
Downers Grove, Illinois, Vereinigte Staaten, 60515
- Rekrutierung
- Advocate Good Samaritan Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-275-1270
- E-Mail: Barbara.barhamand@advocatehealth.com
-
Hauptermittler:
- Rebecca E. McFall
-
Effingham, Illinois, Vereinigte Staaten, 62401
- Rekrutierung
- Carle Physician Group-Effingham
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-Mail: Research@carle.com
-
Hauptermittler:
- Priyank P. Patel
-
Effingham, Illinois, Vereinigte Staaten, 62401
- Rekrutierung
- Crossroads Cancer Center
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-Mail: morganthaler.jodi@mhsil.com
-
Elgin, Illinois, Vereinigte Staaten, 60123
- Rekrutierung
- Advocate Sherman Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-429-2907
-
Hauptermittler:
- Rebecca E. McFall
-
Elmhurst, Illinois, Vereinigte Staaten, 60126
- Rekrutierung
- Elmhurst Memorial Hospital
-
Hauptermittler:
- Joseph Heng
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-758-5460
- E-Mail: Jrohde@emhc.org
-
Evanston, Illinois, Vereinigte Staaten, 60201
- Rekrutierung
- NorthShore University HealthSystem-Evanston Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-570-2109
-
Hauptermittler:
- Robert M. Eisner
-
Geneva, Illinois, Vereinigte Staaten, 60134
- Rekrutierung
- Northwestern Medicine Cancer Center Delnor
-
Hauptermittler:
- Jane N. Winter
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-352-5360
- E-Mail: Donald.Smith3@nm.org
-
Glenview, Illinois, Vereinigte Staaten, 60026
- Rekrutierung
- NorthShore University HealthSystem-Glenbrook Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-570-2109
-
Hauptermittler:
- Robert M. Eisner
-
Glenview, Illinois, Vereinigte Staaten, 60026
- Aktiv, nicht rekrutierend
- Northwestern Medicine Glenview Outpatient Center
-
Grayslake, Illinois, Vereinigte Staaten, 60030
- Aktiv, nicht rekrutierend
- Northwestern Medicine Grayslake Outpatient Center
-
Hazel Crest, Illinois, Vereinigte Staaten, 60429
- Rekrutierung
- Advocate South Suburban Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 708-799-9995
-
Hauptermittler:
- Rebecca E. McFall
-
Highland Park, Illinois, Vereinigte Staaten, 60035
- Rekrutierung
- NorthShore University HealthSystem-Highland Park Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-570-2109
-
Hauptermittler:
- Robert M. Eisner
-
Lake Forest, Illinois, Vereinigte Staaten, 60045
- Aktiv, nicht rekrutierend
- Northwestern Medicine Lake Forest Hospital
-
Libertyville, Illinois, Vereinigte Staaten, 60048
- Rekrutierung
- AMG Libertyville - Oncology
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-929-6129
- E-Mail: advocateresearch@advocatehealth.com
-
Hauptermittler:
- Rebecca E. McFall
-
Libertyville, Illinois, Vereinigte Staaten, 60048
- Rekrutierung
- Condell Memorial Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-929-6129
- E-Mail: advocateresearch@advocatehealth.com
-
Hauptermittler:
- Rebecca E. McFall
-
Mattoon, Illinois, Vereinigte Staaten, 61938
- Rekrutierung
- Carle Physician Group-Mattoon/Charleston
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-Mail: Research@carle.com
-
Hauptermittler:
- Priyank P. Patel
-
Maywood, Illinois, Vereinigte Staaten, 60153
- Rekrutierung
- Loyola University Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 708-226-4357
-
Hauptermittler:
- Eugene Suh
-
Naperville, Illinois, Vereinigte Staaten, 60540
- Rekrutierung
- Edward Hospital/Cancer Center
-
Hauptermittler:
- Joseph Heng
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-646-6075
-
O'Fallon, Illinois, Vereinigte Staaten, 62269
- Rekrutierung
- HSHS Saint Elizabeth's Hospital
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-876-4762
- E-Mail: morganthaler.jodi@mhsil.com
-
Oak Lawn, Illinois, Vereinigte Staaten, 60453-2699
- Rekrutierung
- Advocate Christ Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-323-8622
-
Hauptermittler:
- Rebecca E. McFall
-
Oak Lawn, Illinois, Vereinigte Staaten, 60453
- Rekrutierung
- Advocate Children's Hospital-Oak Lawn
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-723-7570
-
Hauptermittler:
- Rebecca E. McFall
-
Orland Park, Illinois, Vereinigte Staaten, 60462
- Rekrutierung
- Northwestern Medicine Orland Park
-
Hauptermittler:
- Jane N. Winter
-
Kontakt:
- Site Public Contact
- E-Mail: nctnprogram_rhlccc@northwestern.edu
-
Park Ridge, Illinois, Vereinigte Staaten, 60068
- Rekrutierung
- Advocate Lutheran General Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-384-3621
-
Hauptermittler:
- Rebecca E. McFall
-
Park Ridge, Illinois, Vereinigte Staaten, 60068
- Rekrutierung
- Advocate Children's Hospital-Park Ridge
-
Kontakt:
- Site Public Contact
- E-Mail: helpdesk@childrensoncologygroup.org
-
Hauptermittler:
- Rebecca E. McFall
-
Peoria, Illinois, Vereinigte Staaten, 61637
- Rekrutierung
- OSF Children's Hospital of Illinois
-
Hauptermittler:
- Prerna Kumar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-624-4945
- E-Mail: ChildrensHospitalofIllinois@osfhealthcare.org
-
Plainfield, Illinois, Vereinigte Staaten, 60585
- Rekrutierung
- Edward Hospital/Cancer Center?Plainfield
-
Hauptermittler:
- Joseph Heng
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-646-6075
- E-Mail: Cancerresearch@edward.org
-
Rockford, Illinois, Vereinigte Staaten, 61114
- Rekrutierung
- UW Health Carbone Cancer Center Rockford
-
Kontakt:
- Site Public Contact
- Telefonnummer: 779-696-9378
- E-Mail: lkline@uwhealth.org
-
Hauptermittler:
- Fahrettin Covut
-
Shiloh, Illinois, Vereinigte Staaten, 62269
- Rekrutierung
- Memorial Hospital East
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-747-9912
- E-Mail: dschwab@wustl.edu
-
Hauptermittler:
- Nancy L. Bartlett
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Rekrutierung
- Southern Illinois University School of Medicine
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-545-7929
-
Hauptermittler:
- Gregory P. Brandt
-
Urbana, Illinois, Vereinigte Staaten, 61801
- Rekrutierung
- Carle Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-446-5532
- E-Mail: Research@carle.com
-
Hauptermittler:
- Priyank P. Patel
-
Warrenville, Illinois, Vereinigte Staaten, 60555
- Rekrutierung
- Northwestern Medicine Cancer Center Warrenville
-
Hauptermittler:
- Jane N. Winter
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-352-5360
- E-Mail: Donald.Smith3@nm.org
-
Yorkville, Illinois, Vereinigte Staaten, 60560
- Suspendiert
- Rush-Copley Healthcare Center
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 46202
- Rekrutierung
- Riley Hospital for Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-248-1199
-
Hauptermittler:
- Jennifer A. Belsky
-
Indianapolis, Indiana, Vereinigte Staaten, 46260
- Rekrutierung
- Ascension Saint Vincent Indianapolis Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 317-338-2194
- E-Mail: research@stvincent.org
-
Hauptermittler:
- Bassem I. Razzouk
-
-
Iowa
-
Ankeny, Iowa, Vereinigte Staaten, 50023
- Rekrutierung
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-3305
-
Hauptermittler:
- Seema Harichand-Herdt
-
Carroll, Iowa, Vereinigte Staaten, 51401
- Rekrutierung
- Saint Anthony Regional Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-689-7658
- E-Mail: sbenson@iora.org
-
Hauptermittler:
- Seema Harichand-Herdt
-
Clive, Iowa, Vereinigte Staaten, 50325
- Rekrutierung
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-3305
-
Hauptermittler:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Vereinigte Staaten, 50309
- Rekrutierung
- Blank Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-8912
- E-Mail: samantha.mallory@unitypoint.org
-
Hauptermittler:
- Samantha L. Mallory
-
Des Moines, Iowa, Vereinigte Staaten, 50309
- Rekrutierung
- Iowa Methodist Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-6727
-
Hauptermittler:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Vereinigte Staaten, 50309
- Rekrutierung
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-3305
-
Hauptermittler:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Vereinigte Staaten, 50314
- Rekrutierung
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-3305
-
Hauptermittler:
- Seema Harichand-Herdt
-
Iowa City, Iowa, Vereinigte Staaten, 52242
- Rekrutierung
- University of Iowa/Holden Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-237-1225
-
Hauptermittler:
- Andrew P. Groves
-
Waukee, Iowa, Vereinigte Staaten, 50263
- Rekrutierung
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-3305
-
Hauptermittler:
- Seema Harichand-Herdt
-
-
Kansas
-
Wichita, Kansas, Vereinigte Staaten, 67214
- Rekrutierung
- Wesley Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 316-962-7802
- E-Mail: WesleyResearch@wesleymc.com
-
Hauptermittler:
- Nathan S. Hall
-
-
Kentucky
-
Lexington, Kentucky, Vereinigte Staaten, 40536
- Rekrutierung
- University of Kentucky/Markey Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 859-257-3379
-
Hauptermittler:
- James T. Badgett
-
Louisville, Kentucky, Vereinigte Staaten, 40202
- Rekrutierung
- Norton Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 502-629-5500
- E-Mail: CancerResource@nortonhealthcare.org
-
Hauptermittler:
- Michael J. Ferguson
-
Louisville, Kentucky, Vereinigte Staaten, 40202
- Rekrutierung
- The James Graham Brown Cancer Center at University of Louisville
-
Kontakt:
- Site Public Contact
- Telefonnummer: 502-562-3429
-
Hauptermittler:
- Hassaan Yasin
-
Louisville, Kentucky, Vereinigte Staaten, 40245
- Rekrutierung
- UofL Health Medical Center Northeast
-
Kontakt:
- Site Public Contact
- Telefonnummer: 502-852-2755
- E-Mail: ctoinfo@louisville.edu
-
Hauptermittler:
- Hassaan Yasin
-
-
Louisiana
-
New Orleans, Louisiana, Vereinigte Staaten, 70118
- Rekrutierung
- Children's Hospital New Orleans
-
Hauptermittler:
- Maria C. Velez-Yanguas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 504-894-5377
-
New Orleans, Louisiana, Vereinigte Staaten, 70121
- Rekrutierung
- Ochsner Medical Center Jefferson
-
Kontakt:
- Site Public Contact
- Telefonnummer: 504-842-8084
- E-Mail: Elisemarie.curry@ochsner.org
-
Hauptermittler:
- Craig Lotterman
-
-
Maine
-
Bangor, Maine, Vereinigte Staaten, 04401
- Rekrutierung
- Eastern Maine Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-973-4274
-
Hauptermittler:
- Daniel L. Callaway
-
Bath, Maine, Vereinigte Staaten, 04530
- Rekrutierung
- MaineHealth Coastal Cancer Treatment Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-823-5923
- E-Mail: ctsucontact@westat.com
-
Hauptermittler:
- Nadav L. Kastle
-
Portland, Maine, Vereinigte Staaten, 04102
- Rekrutierung
- MaineHealth Maine Medical Center - Portland
-
Hauptermittler:
- Nadav L. Kastle
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-396-8670
- E-Mail: clinicalresearch@mainehealth.org
-
Sanford, Maine, Vereinigte Staaten, 04073
- Rekrutierung
- MaineHealth Cancer Care Center of York County
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-459-1600
-
Hauptermittler:
- Nadav L. Kastle
-
Scarborough, Maine, Vereinigte Staaten, 04074
- Rekrutierung
- Maine Children's Cancer Program
-
Hauptermittler:
- Nadav L. Kastle
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-396-8670
- E-Mail: clinicalresearch@mainehealth.org
-
Scarborough, Maine, Vereinigte Staaten, 04074
- Rekrutierung
- MaineHealth Maine Medical Center- Scarborough
-
Hauptermittler:
- Nadav L. Kastle
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-396-8670
- E-Mail: clinicalresearch@mainehealth.org
-
South Portland, Maine, Vereinigte Staaten, 04106
- Rekrutierung
- MaineHealth Cancer Care and IV Therapy - South Portland
-
Hauptermittler:
- Nadav L. Kastle
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-396-8670
- E-Mail: clinicalresearch@mainehealth.org
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21287
- Rekrutierung
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Hauptermittler:
- Stacy L. Cooper
-
Kontakt:
- Site Public Contact
- Telefonnummer: 410-955-8804
- E-Mail: jhcccro@jhmi.edu
-
Baltimore, Maryland, Vereinigte Staaten, 21215
- Rekrutierung
- Sinai Hospital of Baltimore
-
Hauptermittler:
- Jason M. Fixler
-
Kontakt:
- Site Public Contact
- Telefonnummer: 410-601-9083
-
Baltimore, Maryland, Vereinigte Staaten, 21201
- Rekrutierung
- University of Maryland/Greenebaum Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-888-8823
-
Hauptermittler:
- Teresa A. York
-
Bethesda, Maryland, Vereinigte Staaten, 20889-5600
- Rekrutierung
- Walter Reed National Military Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 301-319-2100
-
Hauptermittler:
- Kip R. Hartman
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Rekrutierung
- Dana-Farber Cancer Institute
-
Hauptermittler:
- Ann S. LaCasce
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-442-3324
-
Worcester, Massachusetts, Vereinigte Staaten, 01655
- Rekrutierung
- UMass Memorial Medical Center - University Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 508-856-3216
- E-Mail: cancer.research@umassmed.edu
-
Hauptermittler:
- Stefanie R. Lowas
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- Rekrutierung
- C S Mott Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-865-1125
-
Hauptermittler:
- Emily B. Walling
-
Ann Arbor, Michigan, Vereinigte Staaten, 48106
- Rekrutierung
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Christopher M. Reynolds
-
Battle Creek, Michigan, Vereinigte Staaten, 49017
- Rekrutierung
- Bronson Battle Creek
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-Mail: crcwm-regulatory@crcwm.org
-
Hauptermittler:
- Kathleen Y. Butler
-
Brighton, Michigan, Vereinigte Staaten, 48114
- Rekrutierung
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Christopher M. Reynolds
-
Brownstown, Michigan, Vereinigte Staaten, 48183
- Rekrutierung
- Henry Ford Cancer Institute-Downriver
-
Kontakt:
- Site Public Contact
- Telefonnummer: 313-916-3721
- E-Mail: CTOResearch@hfhs.org
-
Hauptermittler:
- Philip Kuriakose
-
Canton, Michigan, Vereinigte Staaten, 48188
- Rekrutierung
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Christopher M. Reynolds
-
Chelsea, Michigan, Vereinigte Staaten, 48118
- Rekrutierung
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Christopher M. Reynolds
-
Clinton Township, Michigan, Vereinigte Staaten, 48038
- Rekrutierung
- Henry Ford Macomb Hospital-Clinton Township
-
Kontakt:
- Site Public Contact
- Telefonnummer: 313-916-3721
- E-Mail: CTOResearch@hfhs.org
-
Hauptermittler:
- Philip Kuriakose
-
Dearborn, Michigan, Vereinigte Staaten, 48126
- Rekrutierung
- Henry Ford Medical Center-Fairlane
-
Kontakt:
- Site Public Contact
- Telefonnummer: 313-916-3721
- E-Mail: CTOResearch@hfhs.org
-
Hauptermittler:
- Philip Kuriakose
-
Dearborn, Michigan, Vereinigte Staaten, 48124
- Rekrutierung
- Corewell Health Dearborn Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 248-551-7695
-
Hauptermittler:
- Marie V. Nelson
-
Detroit, Michigan, Vereinigte Staaten, 48201
- Rekrutierung
- Wayne State University/Karmanos Cancer Institute
-
Hauptermittler:
- Vijendra Singh
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-527-6266
- E-Mail: ctoadmin@karmanos.org
-
Detroit, Michigan, Vereinigte Staaten, 48202
- Rekrutierung
- Henry Ford Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 313-916-3721
- E-Mail: CTOResearch@hfhs.org
-
Hauptermittler:
- Philip Kuriakose
-
Detroit, Michigan, Vereinigte Staaten, 48201
- Rekrutierung
- Children's Hospital of Michigan
-
Kontakt:
- Site Public Contact
- E-Mail: helpdesk@childrensoncologygroup.org
-
Hauptermittler:
- Meret Henry
-
East Lansing, Michigan, Vereinigte Staaten, 48823
- Aktiv, nicht rekrutierend
- Michigan State University
-
Farmington Hills, Michigan, Vereinigte Staaten, 48334
- Rekrutierung
- Weisberg Cancer Treatment Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 313-576-9790
- E-Mail: ctoadmin@karmanos.org
-
Hauptermittler:
- Vijendra Singh
-
Farmington Hills, Michigan, Vereinigte Staaten, 48336
- Rekrutierung
- Corewell Health Farmington Hills Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 248-551-7695
-
Hauptermittler:
- Marie V. Nelson
-
Grand Rapids, Michigan, Vereinigte Staaten, 49503
- Rekrutierung
- Trinity Health Grand Rapids Hospital
-
Hauptermittler:
- Christopher M. Reynolds
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-Mail: crcwm-regulatory@crcwm.org
-
Grand Rapids, Michigan, Vereinigte Staaten, 49503
- Rekrutierung
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-Mail: crcwm-regulatory@crcwm.org
-
Hauptermittler:
- Kathleen Y. Butler
-
Grand Rapids, Michigan, Vereinigte Staaten, 49503
- Rekrutierung
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-Mail: crcwm-regulatory@crcwm.org
-
Hauptermittler:
- Kathleen Y. Butler
-
Jackson, Michigan, Vereinigte Staaten, 49201
- Rekrutierung
- Allegiance Health
-
Kontakt:
- Site Public Contact
- Telefonnummer: 313-916-3721
- E-Mail: CTOResearch@hfhs.org
-
Hauptermittler:
- Philip Kuriakose
-
Kalamazoo, Michigan, Vereinigte Staaten, 49007
- Rekrutierung
- Bronson Methodist Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-Mail: crcwm-regulatory@crcwm.org
-
Hauptermittler:
- Kathleen Y. Butler
-
Kalamazoo, Michigan, Vereinigte Staaten, 49007
- Rekrutierung
- West Michigan Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-Mail: crcwm-regulatory@crcwm.org
-
Hauptermittler:
- Kathleen Y. Butler
-
Kalamazoo, Michigan, Vereinigte Staaten, 49009
- Rekrutierung
- Beacon Kalamazoo Cancer Center
-
Hauptermittler:
- Kathleen Y. Butler
-
Kontakt:
- Site Public Contact
- Telefonnummer: 574-647-7370
-
Livonia, Michigan, Vereinigte Staaten, 48154
- Rekrutierung
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Christopher M. Reynolds
-
Macomb, Michigan, Vereinigte Staaten, 48044
- Rekrutierung
- Henry Ford Saint John Hospital - Macomb Medical
-
Hauptermittler:
- Christopher M. Reynolds
-
Kontakt:
- Site Public Contact
- Telefonnummer: 313-343-3166
- E-Mail: kforman1@hfhs.org
-
Muskegon, Michigan, Vereinigte Staaten, 49444
- Suspendiert
- Trinity Health Muskegon Hospital
-
Norton Shores, Michigan, Vereinigte Staaten, 49444
- Rekrutierung
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Hauptermittler:
- Christopher M. Reynolds
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-Mail: connie.szczepanek@crcwm.org
-
Novi, Michigan, Vereinigte Staaten, 48377
- Rekrutierung
- Henry Ford Medical Center-Columbus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 313-916-3721
- E-Mail: CTOResearch@hfhs.org
-
Hauptermittler:
- Philip Kuriakose
-
Novi, Michigan, Vereinigte Staaten, 48374
- Suspendiert
- Henry Ford Health Providence Novi Hospital
-
Pontiac, Michigan, Vereinigte Staaten, 48341
- Rekrutierung
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Christopher M. Reynolds
-
Reed City, Michigan, Vereinigte Staaten, 49677
- Rekrutierung
- Corewell Health Reed City Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-Mail: crcwm-regulatory@crcwm.org
-
Hauptermittler:
- Kathleen Y. Butler
-
Royal Oak, Michigan, Vereinigte Staaten, 48073
- Rekrutierung
- Corewell Health William Beaumont University Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 248-551-7695
-
Hauptermittler:
- Marie V. Nelson
-
Royal Oak, Michigan, Vereinigte Staaten, 48073
- Rekrutierung
- Corewell Health Children's
-
Kontakt:
- Site Public Contact
- Telefonnummer: 248-551-7695
-
Hauptermittler:
- Marie V. Nelson
-
Saint Joseph, Michigan, Vereinigte Staaten, 49085
- Rekrutierung
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-Mail: crcwm-regulatory@crcwm.org
-
Hauptermittler:
- Kathleen Y. Butler
-
Southfield, Michigan, Vereinigte Staaten, 48075
- Suspendiert
- Henry Ford Health Providence Southfield Hospital
-
Traverse City, Michigan, Vereinigte Staaten, 49684
- Rekrutierung
- Munson Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-Mail: crcwm-regulatory@crcwm.org
-
Hauptermittler:
- Kathleen Y. Butler
-
Troy, Michigan, Vereinigte Staaten, 48085
- Rekrutierung
- Corewell Health Beaumont Troy Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 248-551-7695
-
Hauptermittler:
- Marie V. Nelson
-
West Bloomfield, Michigan, Vereinigte Staaten, 48322
- Rekrutierung
- Henry Ford West Bloomfield Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 313-916-3721
- E-Mail: CTOResearch@hfhs.org
-
Hauptermittler:
- Philip Kuriakose
-
Wyandotte, Michigan, Vereinigte Staaten, 48192
- Rekrutierung
- Henry Ford Wyandotte Hospital
-
Kontakt:
- Site Public Contact
- E-Mail: nhay@hfhs.org
-
Hauptermittler:
- Philip Kuriakose
-
Wyoming, Michigan, Vereinigte Staaten, 49519
- Rekrutierung
- University of Michigan Health - West
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-Mail: crcwm-regulatory@crcwm.org
-
Hauptermittler:
- Kathleen Y. Butler
-
Ypsilanti, Michigan, Vereinigte Staaten, 48197
- Rekrutierung
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 734-712-7251
- E-Mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hauptermittler:
- Christopher M. Reynolds
-
-
Minnesota
-
Coon Rapids, Minnesota, Vereinigte Staaten, 55433
- Rekrutierung
- Mercy Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Edina, Minnesota, Vereinigte Staaten, 55435
- Rekrutierung
- Fairview Southdale Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Edina, Minnesota, Vereinigte Staaten, 55435
- Rekrutierung
- Minnesota Oncology - Edina
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Minneapolis, Minnesota, Vereinigte Staaten, 55404
- Rekrutierung
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Hauptermittler:
- Michael K. Richards
-
Kontakt:
- Site Public Contact
- Telefonnummer: 612-813-5913
- E-Mail: pauline.mitby@childrensmn.org
-
Minneapolis, Minnesota, Vereinigte Staaten, 55407
- Rekrutierung
- Abbott-Northwestern Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Minneapolis, Minnesota, Vereinigte Staaten, 55455
- Rekrutierung
- University of Minnesota/Masonic Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 612-624-2620
-
Hauptermittler:
- Peter M. Gordon
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- Rekrutierung
- Mayo Clinic in Rochester
-
Hauptermittler:
- Mira Kohorst
-
Kontakt:
- Site Public Contact
- Telefonnummer: 855-776-0015
-
Saint Louis Park, Minnesota, Vereinigte Staaten, 55416
- Rekrutierung
- Park Nicollet Clinic - Saint Louis Park
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Saint Paul, Minnesota, Vereinigte Staaten, 55101
- Rekrutierung
- Regions Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Saint Paul, Minnesota, Vereinigte Staaten, 55102
- Rekrutierung
- United Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
Woodbury, Minnesota, Vereinigte Staaten, 55125
- Rekrutierung
- Minnesota Oncology Hematology PA-Woodbury
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-Mail: mmcorc@healthpartners.com
-
Hauptermittler:
- David M. King
-
-
Mississippi
-
Jackson, Mississippi, Vereinigte Staaten, 39216
- Rekrutierung
- University of Mississippi Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 601-815-6700
-
Hauptermittler:
- Amanda Strobel
-
-
Missouri
-
Cape Girardeau, Missouri, Vereinigte Staaten, 63703
- Rekrutierung
- Saint Francis Medical Center
-
Hauptermittler:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 573-334-2230
- E-Mail: sfmc@sfmc.net
-
Chesterfield, Missouri, Vereinigte Staaten, 63017
- Rekrutierung
- Saint Luke's Hospital
-
Hauptermittler:
- Mark J. Fesler
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-205-6936
-
City of Saint Peters, Missouri, Vereinigte Staaten, 63376
- Rekrutierung
- Siteman Cancer Center at Saint Peters Hospital
-
Hauptermittler:
- Nancy L. Bartlett
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-Mail: info@siteman.wustl.edu
-
Columbia, Missouri, Vereinigte Staaten, 65212
- Rekrutierung
- University of Missouri Children's Hospital
-
Hauptermittler:
- Barbara A. Gruner
-
Kontakt:
- Site Public Contact
- Telefonnummer: 573-882-1960
- E-Mail: snwq62@health.missouri.edu
-
Creve Coeur, Missouri, Vereinigte Staaten, 63141
- Rekrutierung
- Siteman Cancer Center at West County Hospital
-
Hauptermittler:
- Nancy L. Bartlett
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-Mail: info@siteman.wustl.edu
-
Kansas City, Missouri, Vereinigte Staaten, 64108
- Rekrutierung
- Children's Mercy Hospitals and Clinics
-
Hauptermittler:
- Keith J. August
-
Kontakt:
- Site Public Contact
- Telefonnummer: 816-302-6808
- E-Mail: COGResearchGroup@cmh.edu
-
St Louis, Missouri, Vereinigte Staaten, 63110
- Rekrutierung
- Washington University School of Medicine
-
Hauptermittler:
- Nancy L. Bartlett
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-Mail: info@siteman.wustl.edu
-
St Louis, Missouri, Vereinigte Staaten, 63141
- Rekrutierung
- Mercy Hospital Saint Louis
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-251-7066
-
Hauptermittler:
- Robin D. Hanson
-
St Louis, Missouri, Vereinigte Staaten, 63104
- Rekrutierung
- Cardinal Glennon Children's Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-268-4000
-
Hauptermittler:
- William S. Ferguson
-
St Louis, Missouri, Vereinigte Staaten, 63129
- Rekrutierung
- Siteman Cancer Center-South County
-
Hauptermittler:
- Nancy L. Bartlett
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-Mail: info@siteman.wustl.edu
-
St Louis, Missouri, Vereinigte Staaten, 63136
- Rekrutierung
- Siteman Cancer Center at Christian Hospital
-
Hauptermittler:
- Nancy L. Bartlett
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-Mail: info@siteman.wustl.edu
-
-
Nebraska
-
Bellevue, Nebraska, Vereinigte Staaten, 68123
- Rekrutierung
- Nebraska Medicine-Bellevue
-
Kontakt:
- Site Public Contact
- Telefonnummer: 402-559-6941
- E-Mail: unmcrsa@unmc.edu
-
Hauptermittler:
- Jill C. Beck
-
Omaha, Nebraska, Vereinigte Staaten, 68114
- Rekrutierung
- Children's Hospital and Medical Center of Omaha
-
Kontakt:
- Site Public Contact
- Telefonnummer: 402-955-3949
-
Hauptermittler:
- Jill C. Beck
-
Omaha, Nebraska, Vereinigte Staaten, 68198
- Rekrutierung
- University of Nebraska Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 402-559-6941
- E-Mail: unmcrsa@unmc.edu
-
Hauptermittler:
- Jill C. Beck
-
Omaha, Nebraska, Vereinigte Staaten, 68118
- Rekrutierung
- Nebraska Medicine-Village Pointe
-
Kontakt:
- Site Public Contact
- Telefonnummer: 402-559-5600
-
Hauptermittler:
- Jill C. Beck
-
-
Nevada
-
Las Vegas, Nevada, Vereinigte Staaten, 89135
- Rekrutierung
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Kontakt:
- Site Public Contact
- Telefonnummer: 702-384-0013
- E-Mail: research@sncrf.org
-
Hauptermittler:
- Joseph L. Lasky
-
Reno, Nevada, Vereinigte Staaten, 89502
- Rekrutierung
- Renown Regional Medical Center
-
Hauptermittler:
- Seema L. Rao
-
Kontakt:
- Site Public Contact
- Telefonnummer: 775-982-5050
- E-Mail: Renown-CRD@renown.org
-
-
New Hampshire
-
Lebanon, New Hampshire, Vereinigte Staaten, 03756
- Rekrutierung
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Hauptermittler:
- Angela Ricci
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-639-6918
- E-Mail: cancer.research.nurse@dartmouth.edu
-
-
New Jersey
-
Camden, New Jersey, Vereinigte Staaten, 08103
- Rekrutierung
- Cooper Hospital University Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 856-325-6757
-
Hauptermittler:
- Sushil Ghimire
-
Elizabeth, New Jersey, Vereinigte Staaten, 07207
- Rekrutierung
- Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 908-994-8000
-
Hauptermittler:
- Richard A. Drachtman
-
Flemington, New Jersey, Vereinigte Staaten, 08822
- Rekrutierung
- Hunterdon Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 908-237-2330
-
Hauptermittler:
- Myron E. Bednar
-
Hackensack, New Jersey, Vereinigte Staaten, 07601
- Rekrutierung
- Hackensack University Medical Center
-
Hauptermittler:
- Burton E. Appel
-
Kontakt:
- Site Public Contact
- Telefonnummer: 551-996-2897
-
Jersey City, New Jersey, Vereinigte Staaten, 07302
- Rekrutierung
- Jersey City Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-823-5923
- E-Mail: ctsucontact@westat.com
-
Hauptermittler:
- Richard A. Drachtman
-
Livingston, New Jersey, Vereinigte Staaten, 07039
- Rekrutierung
- Cooperman Barnabas Medical Center
-
Hauptermittler:
- Richard A. Drachtman
-
Kontakt:
- Site Public Contact
- Telefonnummer: 973-322-5200
-
Long Branch, New Jersey, Vereinigte Staaten, 07740
- Rekrutierung
- Monmouth Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-923-6564
- E-Mail: mary.danish@rwjbh.org
-
Hauptermittler:
- Richard A. Drachtman
-
Morristown, New Jersey, Vereinigte Staaten, 07960
- Rekrutierung
- Morristown Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 973-971-5900
-
Hauptermittler:
- Kathryn L. Laurie
-
Neptune City, New Jersey, Vereinigte Staaten, 07753
- Rekrutierung
- Jersey Shore Medical Center
-
Hauptermittler:
- Burton E. Appel
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-776-4240
-
New Brunswick, New Jersey, Vereinigte Staaten, 08903
- Rekrutierung
- Rutgers Cancer Institute of New Jersey
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-235-7356
-
Hauptermittler:
- Richard A. Drachtman
-
New Brunswick, New Jersey, Vereinigte Staaten, 08901
- Rekrutierung
- Saint Peter's University Hospital
-
Hauptermittler:
- Nibal A. Zaghloul
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-745-8600
- E-Mail: officeofresearch@saintpetersuh.com
-
New Brunswick, New Jersey, Vereinigte Staaten, 08903
- Rekrutierung
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-235-8675
-
Hauptermittler:
- Richard A. Drachtman
-
Newark, New Jersey, Vereinigte Staaten, 07112
- Rekrutierung
- Newark Beth Israel Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 973-926-7230
- E-Mail: Christine.Kosmides@rwjbh.org
-
Hauptermittler:
- Teena Bhatla
-
Paterson, New Jersey, Vereinigte Staaten, 07503
- Rekrutierung
- Saint Joseph's Regional Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 973-754-2207
- E-Mail: HallL@sjhmc.org
-
Hauptermittler:
- Alissa Kahn
-
Toms River, New Jersey, Vereinigte Staaten, 08755
- Rekrutierung
- Community Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-557-8294
- E-Mail: Lennette.Gonzales@rwjbh.org
-
Hauptermittler:
- Richard A. Drachtman
-
-
New Mexico
-
Albuquerque, New Mexico, Vereinigte Staaten, 87106
- Rekrutierung
- Presbyterian Hospital
-
Hauptermittler:
- Beeling Armijo
-
Kontakt:
- Site Public Contact
- Telefonnummer: 505-559-6113
- E-Mail: wburman@phs.org
-
Albuquerque, New Mexico, Vereinigte Staaten, 87106
- Suspendiert
- University of New Mexico Cancer Center
-
-
New York
-
Albany, New York, Vereinigte Staaten, 12208
- Rekrutierung
- Albany Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 518-262-5513
-
Hauptermittler:
- Lauren R. Weintraub
-
Buffalo, New York, Vereinigte Staaten, 14263
- Rekrutierung
- Roswell Park Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-767-9355
- E-Mail: askroswell@roswellpark.org
-
Hauptermittler:
- Kara M. Kelly
-
Camillus, New York, Vereinigte Staaten, 13031
- Rekrutierung
- Hematology Oncology Associates of CNY at Camillus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 315-472-7504
-
Hauptermittler:
- Steven M. Duffy
-
East Syracuse, New York, Vereinigte Staaten, 13057
- Rekrutierung
- Hematology Oncology Associates of Central New York-East Syracuse
-
Kontakt:
- Site Public Contact
- Telefonnummer: 315-472-7504
-
Hauptermittler:
- Steven M. Duffy
-
Glens Falls, New York, Vereinigte Staaten, 12801
- Aktiv, nicht rekrutierend
- Glens Falls Hospital
-
Mineola, New York, Vereinigte Staaten, 11501
- Rekrutierung
- NYU Langone Hospital - Long Island
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-263-4432
- E-Mail: cancertrials@nyulangone.org
-
Hauptermittler:
- Chana L. Glasser
-
New Hyde Park, New York, Vereinigte Staaten, 11040
- Rekrutierung
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
Kontakt:
- Site Public Contact
- Telefonnummer: 718-470-3460
-
Hauptermittler:
- Arlene S. Redner
-
New York, New York, Vereinigte Staaten, 10032
- Rekrutierung
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
Hauptermittler:
- Nobuko Hijiya
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-342-5162
- E-Mail: cancerclinicaltrials@cumc.columbia.edu
-
New York, New York, Vereinigte Staaten, 10065
- Rekrutierung
- Memorial Sloan Kettering Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-639-7592
-
Hauptermittler:
- Christopher J. Forlenza
-
New York, New York, Vereinigte Staaten, 10016
- Rekrutierung
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Hauptermittler:
- Elizabeth A. Raetz
-
Kontakt:
- Site Public Contact
- E-Mail: CancerTrials@nyulangone.org
-
New York, New York, Vereinigte Staaten, 10029
- Rekrutierung
- Mount Sinai Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-824-7309
- E-Mail: CCTO@mssm.edu
-
Hauptermittler:
- Pamela R. Merola
-
New York, New York, Vereinigte Staaten, 10065
- Rekrutierung
- NYP/Weill Cornell Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-746-1848
-
Hauptermittler:
- Nitya Gulati
-
Rochester, New York, Vereinigte Staaten, 14642
- Rekrutierung
- University of Rochester
-
Kontakt:
- Site Public Contact
- Telefonnummer: 585-275-5830
-
Hauptermittler:
- Carla Casulo
-
Stony Brook, New York, Vereinigte Staaten, 11794
- Rekrutierung
- Stony Brook University Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-862-2215
-
Hauptermittler:
- Laura E. Hogan
-
Syracuse, New York, Vereinigte Staaten, 13210
- Rekrutierung
- State University of New York Upstate Medical University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 315-464-5476
-
Hauptermittler:
- Melanie A. Comito
-
The Bronx, New York, Vereinigte Staaten, 10467
- Rekrutierung
- Montefiore Medical Center - Moses Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 718-379-6866
- E-Mail: eskwak@montefiore.org
-
Hauptermittler:
- Alice Lee
-
Webster, New York, Vereinigte Staaten, 14580
- Rekrutierung
- Wilmot Cancer Institute at Webster
-
Kontakt:
- Site Public Contact
- E-Mail: WCICTOresearch@urmc.rochester.edu
-
Hauptermittler:
- Carla Casulo
-
Williamsville, New York, Vereinigte Staaten, 14221
- Rekrutierung
- Roswell Park Amherst Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-767-9355
- E-Mail: askroswell@roswellpark.org
-
Hauptermittler:
- Kara M. Kelly
-
-
North Carolina
-
Asheville, North Carolina, Vereinigte Staaten, 28801
- Rekrutierung
- Mission Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 828-213-7055
- E-Mail: NCDV.ResearchRegulatory@HCAHealthcare.com
-
Hauptermittler:
- Douglas J. Scothorn
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27599
- Rekrutierung
- UNC Lineberger Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-668-0683
- E-Mail: cancerclinicaltrials@med.unc.edu
-
Hauptermittler:
- Natalie S. Grover
-
Charlotte, North Carolina, Vereinigte Staaten, 28203
- Rekrutierung
- Carolinas Medical Center/Levine Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-804-9376
-
Hauptermittler:
- Joel A. Kaplan
-
Charlotte, North Carolina, Vereinigte Staaten, 28204
- Rekrutierung
- Novant Health Presbyterian Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 980-201-6360
- E-Mail: kashah@novanthealth.org
-
Hauptermittler:
- Holly Edington
-
Durham, North Carolina, Vereinigte Staaten, 27710
- Rekrutierung
- Duke University Medical Center
-
Hauptermittler:
- Jessica M. Sun
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-275-3853
-
Greenville, North Carolina, Vereinigte Staaten, 27834
- Rekrutierung
- East Carolina University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 252-744-1015
- E-Mail: eubankss@ecu.edu
-
Hauptermittler:
- Andrea R. Whitfield
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27157
- Rekrutierung
- Wake Forest University Health Sciences
-
Kontakt:
- Site Public Contact
- Telefonnummer: 336-713-6771
-
Hauptermittler:
- Sarah Supples
-
-
North Dakota
-
Fargo, North Dakota, Vereinigte Staaten, 58122
- Rekrutierung
- Sanford Broadway Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 701-323-5760
- E-Mail: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Hauptermittler:
- Samuel J. Milanovich
-
-
Ohio
-
Akron, Ohio, Vereinigte Staaten, 44308
- Rekrutierung
- Children's Hospital Medical Center of Akron
-
Kontakt:
- Site Public Contact
- Telefonnummer: 330-543-3193
-
Hauptermittler:
- Lauren R. Draper
-
Cincinnati, Ohio, Vereinigte Staaten, 45229
- Rekrutierung
- Cincinnati Children's Hospital Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 513-636-2799
- E-Mail: cancer@cchmc.org
-
Hauptermittler:
- Robin E. Norris
-
Cleveland, Ohio, Vereinigte Staaten, 44195
- Rekrutierung
- Cleveland Clinic Foundation
-
Kontakt:
- Site Public Contact
- Telefonnummer: 866-223-8100
- E-Mail: TaussigResearch@ccf.org
-
Hauptermittler:
- Matteo M. Trucco
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- Rekrutierung
- Rainbow Babies and Childrens Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 216-844-5437
-
Hauptermittler:
- Duncan S. Stearns
-
Columbus, Ohio, Vereinigte Staaten, 43205
- Rekrutierung
- Nationwide Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-722-6039
- E-Mail: Melinda.Triplet@nationwidechildrens.org
-
Hauptermittler:
- Mark A. Ranalli
-
Dayton, Ohio, Vereinigte Staaten, 45404
- Rekrutierung
- Dayton Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-228-4055
-
Hauptermittler:
- Jordan M. Wright
-
Toledo, Ohio, Vereinigte Staaten, 43606
- Rekrutierung
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 419-824-1842
- E-Mail: PCIOncResearch@promedica.org
-
Hauptermittler:
- Jamie L. Dargart
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
- Rekrutierung
- University of Oklahoma Health Sciences Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 405-271-8777
- E-Mail: ou-clinical-trials@ouhsc.edu
-
Hauptermittler:
- Rene Y. McNall-Knapp
-
Tulsa, Oklahoma, Vereinigte Staaten, 74136
- Rekrutierung
- Saint Francis Children's Hospital
-
Hauptermittler:
- Jill A. Salo
-
Kontakt:
- Site Public Contact
- Telefonnummer: 918-502-6720
-
-
Oregon
-
Baker City, Oregon, Vereinigte Staaten, 97814
- Rekrutierung
- Saint Alphonsus Cancer Care Center-Baker City
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Hauptermittler:
- Christopher M. Reynolds
-
Newberg, Oregon, Vereinigte Staaten, 97132
- Rekrutierung
- Providence Newberg Medical Center
-
Hauptermittler:
- Dan S. Zuckerman
-
Kontakt:
- Site Public Contact
- Telefonnummer: 503-215-2614
- E-Mail: CanRsrchStudies@providence.org
-
Ontario, Oregon, Vereinigte Staaten, 97914
- Rekrutierung
- Saint Alphonsus Cancer Care Center-Ontario
-
Kontakt:
- Site Public Contact
- Telefonnummer: 406-969-6060
- E-Mail: mccinfo@mtcancer.org
-
Hauptermittler:
- Christopher M. Reynolds
-
Oregon City, Oregon, Vereinigte Staaten, 97045
- Rekrutierung
- Providence Willamette Falls Medical Center
-
Hauptermittler:
- Dan S. Zuckerman
-
Kontakt:
- Site Public Contact
- Telefonnummer: 503-215-2614
- E-Mail: CanRsrchStudies@providence.org
-
Portland, Oregon, Vereinigte Staaten, 97227
- Rekrutierung
- Legacy Emanuel Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 503-413-2560
-
Hauptermittler:
- Jason M. Glover
-
Portland, Oregon, Vereinigte Staaten, 97239
- Rekrutierung
- Oregon Health and Science University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 503-494-1080
- E-Mail: trials@ohsu.edu
-
Hauptermittler:
- Bill H. Chang
-
Portland, Oregon, Vereinigte Staaten, 97213
- Rekrutierung
- Providence Portland Medical Center
-
Hauptermittler:
- Dan S. Zuckerman
-
Kontakt:
- Site Public Contact
- Telefonnummer: 503-215-2614
- E-Mail: CanRsrchStudies@providence.org
-
Portland, Oregon, Vereinigte Staaten, 97225
- Rekrutierung
- Providence Saint Vincent Medical Center
-
Hauptermittler:
- Dan S. Zuckerman
-
Kontakt:
- Site Public Contact
- Telefonnummer: 503-215-2614
- E-Mail: CanRsrchStudies@providence.org
-
-
Pennsylvania
-
Allentown, Pennsylvania, Vereinigte Staaten, 18103
- Rekrutierung
- Lehigh Valley Hospital-Cedar Crest
-
Hauptermittler:
- Christopher M. Reynolds
-
Kontakt:
- Site Public Contact
- Telefonnummer: 610-402-9543
- E-Mail: Morgan_M.Horton@lvhn.org
-
Danville, Pennsylvania, Vereinigte Staaten, 17822
- Rekrutierung
- Geisinger Medical Center
-
Hauptermittler:
- Jagadeesh Ramdas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 570-271-5251
- E-Mail: cancerresearch@geisinger.edu
-
Hershey, Pennsylvania, Vereinigte Staaten, 17033
- Rekrutierung
- Penn State Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 717-531-6012
-
Hauptermittler:
- Lisa M. McGregor
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Rekrutierung
- Children's Hospital of Philadelphia
-
Kontakt:
- Site Public Contact
- Telefonnummer: 267-425-5544
- E-Mail: CancerTrials@email.chop.edu
-
Hauptermittler:
- Leslie S. Kersun
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19107
- Rekrutierung
- Thomas Jefferson University Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 215-600-9151
- E-Mail: ONCTrialNow@jefferson.edu
-
Hauptermittler:
- Michael Wysota
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19134
- Rekrutierung
- Saint Christopher's Hospital for Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 215-427-8991
-
Hauptermittler:
- Gregory E. Halligan
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15224
- Rekrutierung
- Children's Hospital of Pittsburgh of UPMC
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-692-8570
- E-Mail: jean.tersak@chp.edu
-
Hauptermittler:
- Jean M. Tersak
-
-
Rhode Island
-
Providence, Rhode Island, Vereinigte Staaten, 02903
- Rekrutierung
- Rhode Island Hospital
-
Hauptermittler:
- Bradley DeNardo
-
Kontakt:
- Site Public Contact
- Telefonnummer: 401-444-1488
-
Westerly, Rhode Island, Vereinigte Staaten, 02891
- Rekrutierung
- Smilow Cancer Hospital Care Center - Westerly
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
Hauptermittler:
- Farzana Pashankar
-
-
South Carolina
-
Boiling Springs, South Carolina, Vereinigte Staaten, 29316
- Rekrutierung
- Prisma Health Cancer Institute - Spartanburg
-
Hauptermittler:
- Aniket Saha
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
Charleston, South Carolina, Vereinigte Staaten, 29425
- Rekrutierung
- Medical University of South Carolina
-
Kontakt:
- Site Public Contact
- Telefonnummer: 843-792-9321
- E-Mail: hcc-clinical-trials@musc.edu
-
Hauptermittler:
- Jacqueline M. Kraveka
-
Columbia, South Carolina, Vereinigte Staaten, 29203
- Rekrutierung
- Prisma Health Richland Hospital
-
Hauptermittler:
- Stuart L. Cramer
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Vereinigte Staaten, 29605
- Rekrutierung
- BI-LO Charities Children's Cancer Center
-
Hauptermittler:
- Aniket Saha
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Vereinigte Staaten, 29601
- Rekrutierung
- Saint Francis Hospital
-
Hauptermittler:
- Stephen H. Dyar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-603-6234
- E-Mail: Heather_Rich@bshsi.org
-
Greenville, South Carolina, Vereinigte Staaten, 29607
- Rekrutierung
- Saint Francis Cancer Center
-
Hauptermittler:
- Stephen H. Dyar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-603-6234
- E-Mail: Heather_Rich@bshsi.org
-
Greenville, South Carolina, Vereinigte Staaten, 29615
- Rekrutierung
- Prisma Health Cancer Institute - Eastside
-
Hauptermittler:
- Aniket Saha
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
Seneca, South Carolina, Vereinigte Staaten, 29672
- Rekrutierung
- Prisma Health Cancer Institute - Seneca
-
Hauptermittler:
- Aniket Saha
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57117-5134
- Rekrutierung
- Sanford USD Medical Center - Sioux Falls
-
Kontakt:
- Site Public Contact
- Telefonnummer: 605-312-3320
- E-Mail: OncologyClinicalTrialsSF@SanfordHealth.org
-
Hauptermittler:
- Jordan Fritch-Hanson
-
-
Tennessee
-
Chattanooga, Tennessee, Vereinigte Staaten, 37403
- Rekrutierung
- T C Thompson Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 423-778-7289
-
Hauptermittler:
- Benjamin A. Mixon
-
Knoxville, Tennessee, Vereinigte Staaten, 37916
- Rekrutierung
- East Tennessee Childrens Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 865-541-8266
-
Hauptermittler:
- Susan E. Spiller
-
Nashville, Tennessee, Vereinigte Staaten, 37232
- Rekrutierung
- Vanderbilt University/Ingram Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-811-8480
-
Hauptermittler:
- Christine M. Smith
-
Nashville, Tennessee, Vereinigte Staaten, 37203
- Rekrutierung
- The Children's Hospital at TriStar Centennial
-
Kontakt:
- Site Public Contact
- Telefonnummer: 615-342-1919
-
Hauptermittler:
- Clinton M. Carroll
-
-
Texas
-
Austin, Texas, Vereinigte Staaten, 78723
- Rekrutierung
- Dell Children's Medical Center of Central Texas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 512-628-1902
- E-Mail: TXAUS-DL-SFCHemonc.research@ascension.org
-
Hauptermittler:
- Shannon M. Cohn
-
Corpus Christi, Texas, Vereinigte Staaten, 78411
- Rekrutierung
- Driscoll Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 361-694-5311
- E-Mail: Crystal.DeLosSantos@dchstx.org
-
Hauptermittler:
- Nkechi I. Mba
-
Dallas, Texas, Vereinigte Staaten, 75390
- Rekrutierung
- UT Southwestern/Simmons Cancer Center-Dallas
-
Hauptermittler:
- Ksenya Shliakhtsitsava
-
Kontakt:
- Site Public Contact
- Telefonnummer: 214-648-7097
- E-Mail: canceranswerline@UTSouthwestern.edu
-
Dallas, Texas, Vereinigte Staaten, 75230
- Rekrutierung
- Medical City Dallas Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 972-566-5588
-
Hauptermittler:
- Maurizio L. Ghisoli
-
El Paso, Texas, Vereinigte Staaten, 79905
- Rekrutierung
- El Paso Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 915-298-5444
- E-Mail: ranjan.bista@ttuhsc.edu
-
Hauptermittler:
- Benjamin Carcamo
-
Fort Worth, Texas, Vereinigte Staaten, 76104
- Rekrutierung
- Cook Children's Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 682-885-2103
- E-Mail: CookChildrensResearch@cookchildrens.org
-
Hauptermittler:
- Karen H. Albritton
-
Houston, Texas, Vereinigte Staaten, 77030
- Rekrutierung
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 713-798-1354
- E-Mail: burton@bcm.edu
-
Hauptermittler:
- Kala Y. Kamdar
-
Houston, Texas, Vereinigte Staaten, 77030
- Rekrutierung
- UT MD Anderson Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 866-632-6789
- E-Mail: askmdanderson@mdanderson.org
-
Hauptermittler:
- Najat C. Daw
-
Lubbock, Texas, Vereinigte Staaten, 79410
- Rekrutierung
- Covenant Children's Hospital
-
Hauptermittler:
- Kishor M. Bhende
-
Kontakt:
- Site Public Contact
- Telefonnummer: 806-725-8657
- E-Mail: mbisbee@providence.org
-
Lubbock, Texas, Vereinigte Staaten, 79415
- Rekrutierung
- UMC Cancer Center / UMC Health System
-
Kontakt:
- Site Public Contact
- Telefonnummer: 806-775-8590
-
Hauptermittler:
- Erin K. Barr
-
San Antonio, Texas, Vereinigte Staaten, 78207
- Rekrutierung
- Children's Hospital of San Antonio
-
Kontakt:
- Site Public Contact
- Telefonnummer: 210-704-2894
- E-Mail: bridget.medina@christushealth.org
-
Hauptermittler:
- Julie Voeller
-
San Antonio, Texas, Vereinigte Staaten, 78229
- Rekrutierung
- University of Texas Health Science Center at San Antonio
-
Kontakt:
- Site Public Contact
- Telefonnummer: 210-450-3800
- E-Mail: phoresearchoffice@uthscsa.edu
-
Hauptermittler:
- Allison C. Grimes
-
San Antonio, Texas, Vereinigte Staaten, 78229
- Rekrutierung
- Methodist Children's Hospital of South Texas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 210-575-6240
- E-Mail: Vinod.GidvaniDiaz@hcahealthcare.com
-
Hauptermittler:
- Jose M. Esquilin
-
Temple, Texas, Vereinigte Staaten, 76508
- Rekrutierung
- Scott and White Memorial Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 254-724-5407
-
Hauptermittler:
- Nicholas W. McGregor
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84113
- Rekrutierung
- Primary Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 801-585-5270
-
Hauptermittler:
- Mallorie B. Heneghan
-
Salt Lake City, Utah, Vereinigte Staaten, 84112
- Rekrutierung
- Huntsman Cancer Institute/University of Utah
-
Hauptermittler:
- Boyu Hu
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-424-2100
- E-Mail: cancerinfo@hci.utah.edu
-
-
Vermont
-
Burlington, Vermont, Vereinigte Staaten, 05405
- Rekrutierung
- University of Vermont and State Agricultural College
-
Kontakt:
- Site Public Contact
- Telefonnummer: 802-656-8990
- E-Mail: rpo@uvm.edu
-
Hauptermittler:
- Jessica L. Heath
-
-
Virginia
-
Charlottesville, Virginia, Vereinigte Staaten, 22908
- Rekrutierung
- University of Virginia Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 434-243-6303
- E-Mail: uvacancertrials@hscmail.mcc.virginia.edu
-
Hauptermittler:
- Brian C. Belyea
-
Falls Church, Virginia, Vereinigte Staaten, 22042
- Rekrutierung
- Inova Fairfax Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 703-208-6650
- E-Mail: Stephanie.VanBebber@inova.org
-
Hauptermittler:
- Robin Y. Dulman
-
Norfolk, Virginia, Vereinigte Staaten, 23507
- Rekrutierung
- Children's Hospital of The King's Daughters
-
Kontakt:
- Site Public Contact
- Telefonnummer: 757-668-7243
- E-Mail: CCBDCresearch@chkd.org
-
Hauptermittler:
- Melissa S. Mark
-
Portsmouth, Virginia, Vereinigte Staaten, 23708-2197
- Rekrutierung
- Naval Medical Center - Portsmouth
-
Kontakt:
- Site Public Contact
- Telefonnummer: 757-953-5939
-
Hauptermittler:
- Karin Brockman
-
Richmond, Virginia, Vereinigte Staaten, 23298
- Rekrutierung
- VCU Massey Comprehensive Cancer Center
-
Hauptermittler:
- Jordyn R. Griffin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 804-628-6430
- E-Mail: CTOclinops@vcu.edu
-
Roanoke, Virginia, Vereinigte Staaten, 24014
- Rekrutierung
- Carilion Children's
-
Kontakt:
- Site Public Contact
- Telefonnummer: 540-266-6238
- E-Mail: wpmccarty@carilionclinic.org
-
Hauptermittler:
- Erwood G. Edwards
-
-
Washington
-
Renton, Washington, Vereinigte Staaten, 98055
- Suspendiert
- Valley Medical Center
-
Seattle, Washington, Vereinigte Staaten, 98105
- Rekrutierung
- Seattle Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 866-987-2000
-
Hauptermittler:
- Sarah E. Leary
-
Spokane, Washington, Vereinigte Staaten, 99204
- Rekrutierung
- Providence Sacred Heart Medical Center and Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-228-6618
- E-Mail: HopeBeginsHere@providence.org
-
Hauptermittler:
- Judy L. Felgenhauer
-
Tacoma, Washington, Vereinigte Staaten, 98405
- Rekrutierung
- Mary Bridge Children's Hospital and Health Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 253-403-1461
- E-Mail: research@multicare.org
-
Hauptermittler:
- Robert G. Irwin
-
-
West Virginia
-
Charleston, West Virginia, Vereinigte Staaten, 25304
- Rekrutierung
- Vandalia Health/CAMC Institute for Academic Medicine
-
Hauptermittler:
- Mohamad H. Badawi
-
Kontakt:
- Site Public Contact
- Telefonnummer: 304-388-9944
- E-Mail: CAMCClinicalTrials@vandaliahealth.org
-
Huntington, West Virginia, Vereinigte Staaten, 25701
- Rekrutierung
- Edwards Comprehensive Cancer Center
-
Hauptermittler:
- Mark A. Ranalli
-
Kontakt:
- Site Public Contact
- Telefonnummer: 304-399-6566
- E-Mail: Christina.Cole@chhi.org
-
-
Wisconsin
-
Burlington, Wisconsin, Vereinigte Staaten, 53105
- Rekrutierung
- Aurora Cancer Care-Southern Lakes VLCC
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Rebecca E. McFall
-
Cudahy, Wisconsin, Vereinigte Staaten, 53110
- Rekrutierung
- Aurora Saint Luke's South Shore
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Rebecca E. McFall
-
Germantown, Wisconsin, Vereinigte Staaten, 53022
- Rekrutierung
- Aurora Health Care Germantown Health Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Rebecca E. McFall
-
Grafton, Wisconsin, Vereinigte Staaten, 53024
- Rekrutierung
- Aurora Cancer Care-Grafton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Rebecca E. McFall
-
Green Bay, Wisconsin, Vereinigte Staaten, 54311
- Rekrutierung
- Aurora BayCare Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Rebecca E. McFall
-
Green Bay, Wisconsin, Vereinigte Staaten, 54301
- Rekrutierung
- Saint Vincent Hospital Cancer Center Green Bay
-
Hauptermittler:
- Catherine A. Long
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-433-8889
- E-Mail: WI_research_admin@hshs.org
-
Kenosha, Wisconsin, Vereinigte Staaten, 53142
- Rekrutierung
- Aurora Cancer Care-Kenosha South
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Rebecca E. McFall
-
La Crosse, Wisconsin, Vereinigte Staaten, 54601
- Rekrutierung
- Gundersen Lutheran Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 608-775-2385
- E-Mail: cancerctr@gundersenhealth.org
-
Hauptermittler:
- Kurt Oettel
-
Madison, Wisconsin, Vereinigte Staaten, 53792
- Rekrutierung
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Hauptermittler:
- Priyanka Pophali
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-622-8922
- E-Mail: clinicaltrials@cancer.wisc.edu
-
Madison, Wisconsin, Vereinigte Staaten, 53718
- Rekrutierung
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Hauptermittler:
- Priyanka Pophali
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-622-8922
- E-Mail: clinicaltrials@cancer.wisc.edu
-
Marinette, Wisconsin, Vereinigte Staaten, 54143
- Rekrutierung
- Aurora Bay Area Medical Group-Marinette
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Rebecca E. McFall
-
Marshfield, Wisconsin, Vereinigte Staaten, 54449
- Rekrutierung
- Marshfield Medical Center-Marshfield
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-Mail: oncology.clinical.trials@marshfieldresearch.org
-
Hauptermittler:
- Michelle A. Manalang
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53226
- Rekrutierung
- Children's Hospital of Wisconsin
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-955-4727
- E-Mail: MACCCTO@mcw.edu
-
Hauptermittler:
- Michael J. Burke
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53209
- Rekrutierung
- Aurora Cancer Care-Milwaukee
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Rebecca E. McFall
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53215
- Rekrutierung
- Aurora Saint Luke's Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Rebecca E. McFall
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53233
- Rekrutierung
- Aurora Sinai Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Rebecca E. McFall
-
Mukwonago, Wisconsin, Vereinigte Staaten, 53149
- Rekrutierung
- ProHealth D N Greenwald Center
-
Kontakt:
- Site Public Contact
- E-Mail: research.institute@phci.org
-
Hauptermittler:
- Timothy R. Wassenaar
-
Oconomowoc, Wisconsin, Vereinigte Staaten, 53066
- Rekrutierung
- ProHealth Oconomowoc Memorial Hospital
-
Hauptermittler:
- Timothy R. Wassenaar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 262-928-7878
-
Oshkosh, Wisconsin, Vereinigte Staaten, 54904
- Rekrutierung
- Vince Lombardi Cancer Clinic - Oshkosh
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Rebecca E. McFall
-
Racine, Wisconsin, Vereinigte Staaten, 53406
- Rekrutierung
- Aurora Cancer Care-Racine
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Rebecca E. McFall
-
Sheboygan, Wisconsin, Vereinigte Staaten, 53081
- Rekrutierung
- Vince Lombardi Cancer Clinic-Sheboygan
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Rebecca E. McFall
-
Sheboygan, Wisconsin, Vereinigte Staaten, 53081
- Rekrutierung
- Saint Vincent Hospital Cancer Center at Sheboygan
-
Hauptermittler:
- Catherine A. Long
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-433-8889
- E-Mail: wi_research_admin@hshs.org
-
Sturgeon Bay, Wisconsin, Vereinigte Staaten, 54235-1495
- Rekrutierung
- Saint Vincent Hospital Cancer Center at Sturgeon Bay
-
Hauptermittler:
- Catherine A. Long
-
Kontakt:
- Site Public Contact
- Telefonnummer: 920-433-8889
- E-Mail: wi_research_admin@hshs.org
-
Summit, Wisconsin, Vereinigte Staaten, 53066
- Rekrutierung
- Aurora Medical Center in Summit
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Rebecca E. McFall
-
Two Rivers, Wisconsin, Vereinigte Staaten, 54241
- Rekrutierung
- Vince Lombardi Cancer Clinic-Two Rivers
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Rebecca E. McFall
-
Waukesha, Wisconsin, Vereinigte Staaten, 53188
- Rekrutierung
- UW Cancer Center at ProHealth Care
-
Hauptermittler:
- Timothy R. Wassenaar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 262-928-5539
- E-Mail: Chanda.miller@phci.org
-
Wauwatosa, Wisconsin, Vereinigte Staaten, 53226
- Rekrutierung
- Aurora Cancer Care-Milwaukee West
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Rebecca E. McFall
-
West Allis, Wisconsin, Vereinigte Staaten, 53227
- Rekrutierung
- Aurora West Allis Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-302-2304
- E-Mail: ncorp@aurora.org
-
Hauptermittler:
- Rebecca E. McFall
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Patients must be 5 to 60 years of age at the time of enrollment
-
Patients with newly diagnosed untreated histologically confirmed classic Hodgkin lymphoma (cHL) (nodular sclerosis, mixed cellularity, lymphocyte-rich, or lymphocyte-depleted, or not otherwise specified [NOS]) with stage I or II disease
-
Patients must have bidimensionally measurable disease (at least one lesion with longest diameter >= 1.5 cm)
-
Patients must have a whole body or limited whole body PET scan performed within 42 days prior to enrollment. PET-CT is strongly preferred. PET-MRI allowed if intravenous contrast enhanced CT is also obtained
-
Pediatric patients (age 5-17 years) with known or suspected mediastinal disease must have an upright posteroanterior (PA) chest X-ray (CXR) for assessment of bulky mediastinal disease.
- Note: Pediatric patients who have received both a CT chest and upright PA CXR may meet the definition of bulk through either modality.
-
Patients >= 18 years must have a performance status corresponding to Zubrod scores of 0, 1 or 2
-
Patients =< 17 years of age must have a Lansky performance score of >= 50
-
Pediatric patients (age 5-17 years): A serum creatinine based on age/sex as follows (within 28 days prior to enrollment):
- 2 to < 6 years (age): 0.8 mg/dL (male), 0.8 mg/dL (female)
- 6 to < 10 years (age): 1 mg/dL (male), 1 mg/dL (female)
- 10 to < 13 years (age): 1.2 mg/dL (male), 1.2 mg/dL (female)
- 13 to < 16 years (age): 1.5 mg/dL (male), 1.4 mg/dL (female)
- >= 16 years (age): 1.7 mg/dL (male), 1.4 mg/dL (female) OR a 24 hour urine creatinine clearance >= 50 mL/min/1.73 m^2 (within 28 days prior to enrollment) OR a glomerular filtration rate (GFR) >= 50 mL/min/1.73 m^2 (within 28 days prior to enrollment). GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard)
- Note: Estimated GFR (eGFR) from serum or plasma creatinine, cystatin C or other estimates are not acceptable for determining eligibility
-
For adult patients (age 18 years or older) (within 28 days prior to enrollment): Creatinine clearance >= 30 mL/min, as estimated by the Cockcroft and Gault formula or a 24-hour urine collection. The creatinine value used in the calculation must have been obtained within 28 days prior to registration. Estimated creatinine clearance is based on actual body weight
-
Total bilirubin =< 2 x upper limit of normal (ULN) (within 28 days prior to enrollment)
- Unless due to Gilbert's disease, lymphomatous involvement of liver or vanishing bile duct syndrome
-
Aspartate aminotransferase (AST) =< 3 x ULN (within 28 days prior to enrollment)
- Unless due to Gilbert's disease, lymphomatous involvement of liver or vanishing bile duct syndrome
-
Alanine aminotransferase (ALT) =< 3 x ULN (within 28 days prior to enrollment)
- Unless due to Gilbert's disease, lymphomatous involvement of liver or vanishing bile duct syndrome
-
Shortening fraction of >= 27% by echocardiogram (ECHO), multigated acquisition scan (MUGA), or functional cardiac imaging scan (within 28 days prior to enrollment) or ejection fraction of >= 50% by radionuclide angiogram, ECHO, MUGA, or cardiac imaging scan (within 28 days prior to enrollment)
-
Diffusion capacity of the lung for carbon monoxide (DLCO) >= 50% of predicted value as corrected for hemoglobin by pulmonary function test (PFT) (within 28 days prior to enrollment). If unable to obtain PFTs, the criterion is: a pulse oximetry reading of > 92% on room air
-
Known human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
Exclusion Criteria:
-
Patients with nodular lymphocyte predominant Hodgkin lymphoma
-
Patients with a history of active interstitial pneumonitis or interstitial lung disease
-
Patients with a diagnosis of inherited or acquired immunodeficiency that is poorly controlled or requiring active medications, such as primary immunodeficiency syndromes or organ transplant recipients
-
Patients with any known uncontrolled intercurrent illness that would jeopardize the patient's safety such as infection, autoimmune conditions, cardiac arrhythmias, angina pectoris, and gastrointestinal disorders affecting swallowing and/or absorption of pills
-
Patients with a condition requiring systemic treatment with either corticosteroids (defined as equivalent to > 10 mg daily predniSONE for patients >= 18 years or > 0.5 mg/kg [up to 10 mg/day] for patients < 18 years) or other immunosuppressive medications within 14 days prior to enrollment
- Note: Replacement therapy such as thyroxine, insulin, or physiologic corticosteroid for adrenal or pituitary insufficiency is not considered a form of systemic treatment. Inhaled or topical steroids, and adrenal replacement doses (=< 10 mg daily for patients >= 18 years or =< 0.5 mg/kg [up to 10 mg/day] predniSONE equivalents) are permitted in the absence of active autoimmune disease
- Note: Steroid use for the control of Hodgkin lymphoma symptoms is allowable, but must be discontinued by cycle 1, day 1
- Short term use of corticosteroids for premedication or treatment of an allergy or hypersensitivity is considered an acceptable use of corticosteroids.
-
Patients with peripheral neuropathy > grade 1 at the time of enrollment or patients with known Charcot-Marie-Tooth syndrome
-
Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen
-
Administration of prior chemotherapy, radiation, or antibody-based treatment for cHL
-
Prior solid organ transplant
-
Prior allogeneic stem cell transplantation
-
Live vaccine within 30 days prior to planned day 1 of protocol therapy (e.g., measles, mumps, rubella, varicella, yellow fever, rabies, bacillus Calmette Guerin [BCG], oral polio vaccine, and oral typhoid). Administration of messenger ribonucleic acid (mRNA) vaccines are permitted
-
Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test within 28 days prior to enrollment is required for female patients of childbearing potential
-
Lactating females who plan to breastfeed their infants starting with the first dose of study therapy and for at least 6 months after the last treatment
-
Sexually active patients of reproductive potential who have not agreed to use a highly effective contraceptive method for the duration of their study drug therapy. Following therapy, patients will be advised to use contraception as per institutional practice or as listed below for investigational agents, whichever is longer
- Men and women of childbearing potential (WOCBP) must use effective contraception during the study and for 2 months for WOCBP and 4 months for men, after last dose of brentuximab vedotin
- WOCBP must continue contraception for a period of at least 5 months after the last dose of nivolumab
-
All patients and/or their parents or legal guardians must sign a written informed consent
-
All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Arm A (ABVD)
Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive ABVD IV for an additional 2 cycles on study. Each cycle lasts 28 days and ABVD is administered on days 1 and 15 of each cycle in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial. |
Given IV
Andere Namen:
Undergo blood sample collection
Andere Namen:
Ancillary studies Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo CT and/or PET-CT
Andere Namen:
Undergo FDG-PET
Andere Namen:
Undergo MRI and/or PET-MRI
Andere Namen:
Undergo FDG-PET, PET, PET-CT, and/or PET-MRI
Andere Namen:
|
|
Experimental: Arm B (ABVD, brentuximab vedotin, nivolumab)
Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30 minutes once during each treatment cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial. |
Given IV
Andere Namen:
Undergo blood sample collection
Andere Namen:
Ancillary studies Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo CT and/or PET-CT
Andere Namen:
Undergo FDG-PET
Andere Namen:
Undergo MRI and/or PET-MRI
Andere Namen:
Undergo FDG-PET, PET, PET-CT, and/or PET-MRI
Andere Namen:
|
|
Experimental: Arm C (ABVD, eBEACOPP or eBPDac, ISRT)
See Detailed Description. |
Given IV
Andere Namen:
Given IV
Andere Namen:
Given PO
Andere Namen:
Undergo blood sample collection
Andere Namen:
Given IV
Andere Namen:
Ancillary studies Given IV
Andere Namen:
Given IV
Andere Namen:
Given PO
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo CT and/or PET-CT
Andere Namen:
Undergo FDG-PET
Andere Namen:
Undergo MRI and/or PET-MRI
Andere Namen:
Undergo FDG-PET, PET, PET-CT, and/or PET-MRI
Andere Namen:
Undergo ISRT
Andere Namen:
Given PO
Andere Namen:
|
|
Experimental: Arm D (ABVD, brentuximab vedotin, nivolumab, ISRT)
Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive brentuximab vedotin IV and nivolumab IV as in arm B followed by ISRT. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial. |
Given IV
Andere Namen:
Undergo blood sample collection
Andere Namen:
Ancillary studies Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo CT and/or PET-CT
Andere Namen:
Undergo FDG-PET
Andere Namen:
Undergo MRI and/or PET-MRI
Andere Namen:
Undergo FDG-PET, PET, PET-CT, and/or PET-MRI
Andere Namen:
Undergo ISRT
Andere Namen:
|
|
Experimental: Arm E (ABVD, AVD)
Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive AVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, vinblastine IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial. |
Given IV
Andere Namen:
Undergo blood sample collection
Andere Namen:
Ancillary studies Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo CT and/or PET-CT
Andere Namen:
Undergo FDG-PET
Andere Namen:
Undergo MRI and/or PET-MRI
Andere Namen:
Undergo FDG-PET, PET, PET-CT, and/or PET-MRI
Andere Namen:
|
|
Experimental: Arm F (ABVD, brentuximab vedotin, nivolumab)
Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive treatment as in arm B. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial. |
Given IV
Andere Namen:
Undergo blood sample collection
Andere Namen:
Ancillary studies Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo CT and/or PET-CT
Andere Namen:
Undergo FDG-PET
Andere Namen:
Undergo MRI and/or PET-MRI
Andere Namen:
Undergo FDG-PET, PET, PET-CT, and/or PET-MRI
Andere Namen:
|
|
Experimental: Arm G (ABVD, eBEACOPP or eBPDac, ISRT)
Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive treatment and imaging, and may undergo blood sample collection as in arm C. |
Given IV
Andere Namen:
Given IV
Andere Namen:
Given PO
Andere Namen:
Undergo blood sample collection
Andere Namen:
Given IV
Andere Namen:
Ancillary studies Given IV
Andere Namen:
Given IV
Andere Namen:
Given PO
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo CT and/or PET-CT
Andere Namen:
Undergo FDG-PET
Andere Namen:
Undergo MRI and/or PET-MRI
Andere Namen:
Undergo FDG-PET, PET, PET-CT, and/or PET-MRI
Andere Namen:
Undergo ISRT
Andere Namen:
Given PO
Andere Namen:
|
|
Experimental: Arm H (ABVD, brentuximab vedotin, nivolumab, ISRT)
Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive treatment and imaging, and may undergo blood sample collection as in arm D. |
Given IV
Andere Namen:
Undergo blood sample collection
Andere Namen:
Ancillary studies Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo CT and/or PET-CT
Andere Namen:
Undergo FDG-PET
Andere Namen:
Undergo MRI and/or PET-MRI
Andere Namen:
Undergo FDG-PET, PET, PET-CT, and/or PET-MRI
Andere Namen:
Undergo ISRT
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Progression-free survival (PFS) in rapid early responder (RER) patients
Zeitfenster: From the time of randomization to the earliest time of disease relapse, progression, or death due to any cause, assessed up to 3 years after the randomization of the last patient or when reaching 124 events, whichever comes first
|
Will compare the PFS of RER patients randomized to immunotherapy (IO) therapy (brentuximab vedotin-nivolumab) against those randomized to standard therapy. PFS curves will be estimated separately by arm using Kaplan Meier methodology, and the test will be a 1-sided log-rank test between the (pooled) IO and standard arms, stratified according to the stratification factors at randomization and including all eligible and evaluable randomized patients. |
From the time of randomization to the earliest time of disease relapse, progression, or death due to any cause, assessed up to 3 years after the randomization of the last patient or when reaching 124 events, whichever comes first
|
|
PFS in slow-early responder (SER) patients
Zeitfenster: From the time of randomization to the earliest time of disease relapse, progression, or death due to any cause, assessed up to 3 years after the randomization of the last patient or when reaching 71 events, whichever comes first
|
Will compare PFS among SER patients randomized to IO therapy and involved-site radiation therapy against arms containing standard therapy. PFS curves will be estimated separately by arm using Kaplan Meier methodology, and the test will be a 1-sided log-rank test between the (pooled) IO and standard arms, stratified according to the stratification factors at randomization and including all eligible and evaluable randomized patients. |
From the time of randomization to the earliest time of disease relapse, progression, or death due to any cause, assessed up to 3 years after the randomization of the last patient or when reaching 71 events, whichever comes first
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Overall survival (OS) in RER patients
Zeitfenster: Time from randomization to death due to any cause, assessed up to 12 years after the last enrollment
|
The non-inferiority of IO therapy to standard therapy will be tested in the randomized and eligible RER cohort using a confidence interval approach performed 12 years after the last patient not lost to follow-up has reached more than 12 years of follow-up (patients are followed up to 13 years). |
Time from randomization to death due to any cause, assessed up to 12 years after the last enrollment
|
|
OS in SER patients
Zeitfenster: Time from randomization to death due to any cause, assessed up to 12 years after the last enrollment
|
Will be compared between a standard chemotherapy approach and an IO therapy approach among the SER patients. |
Time from randomization to death due to any cause, assessed up to 12 years after the last enrollment
|
|
OS for entire patient population
Zeitfenster: Time from randomization to death due to any cause, assessed at 12 years after the last enrollment
|
Will be based on a confidence interval approach conducted after the last patient not lost to follow-up has been followed for at least 12 years from randomization. Twelve-year OS and its corresponding 90% confidence interval will be estimated with the Kaplan-Meier method for each study arm within the entire randomized and evaluable trial population. |
Time from randomization to death due to any cause, assessed at 12 years after the last enrollment
|
|
PFS for favorable risk patients
Zeitfenster: Up to 12 years
|
Will be estimated in patients with favorable features at diagnosis. PFS and a corresponding confidence interval will be estimated using the Kaplan-Meier approach. PFS will also be compared between the (pooled) IO therapy and standard therapy arms using stratified log-rank tests within each cohort. |
Up to 12 years
|
|
PFS for unfavorable risk patients
Zeitfenster: Up to 12 years
|
Will be estimated in patients with unfavorable features at diagnosis. PFS and a corresponding confidence interval will be estimated using the Kaplan-Meier approach. PFS will also be compared between the (pooled) IO therapy and standard therapy arms using stratified log-rank tests within each cohort. |
Up to 12 years
|
|
PFS for entire population
Zeitfenster: Up to 12 years
|
PFS and a corresponding confidence interval will be estimated using the Kaplan-Meier approach. PFS will also be compared between the (pooled) IO therapy and standard therapy arms using stratified log-rank tests within each cohort. |
Up to 12 years
|
|
Event-free survival (EFS)
Zeitfenster: Time from randomization to the earliest of progression, relapse, second malignancy, or death due to any cause, assessed up to 12 years from last enrollment
|
Pooling IO treatment arms and standard treatment arms, EFS and corresponding confidence intervals will be estimated with the Kaplan-Meier approach for patients assigned versus (vs.) not assigned to receive radiaton therapy (RT), and compared using the log-rank test. |
Time from randomization to the earliest of progression, relapse, second malignancy, or death due to any cause, assessed up to 12 years from last enrollment
|
|
Incidence of adverse events (AEs)
Zeitfenster: Assessed up to 12 years from last enrollment
|
Will use the American Society of Clinical Oncology and the Society for Immunotherapy of Cancer guidelines to capture immune-related AEs. Physician-reported treatment related AEs will be reported for all grades using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Rates of individual toxicities with grades greater or equal to 3 will be compared between the pooled IO and standard arms using exact binomial tests. The maximum grade for each toxicity will be recorded for each patient. The rates and confidence intervals for these toxicities will be provided. Comparison of AEs will also be conducted for physician-reported treatment-related AEs between RT and non-RT patients. |
Assessed up to 12 years from last enrollment
|
|
Patient reported outcomes (PRO)-CTCAE
Zeitfenster: Assessed up to 12 years from last enrollment
|
Targeted patient-reported AEs will be collected at each time point using the PRO-CTCAE for patients 7 years and older. For youth (7-17 years) the Pediatric PRO-CTCAE form will be used and for those 18 years and older adult the PRO-CTCAE form will be used. For information collected by each of the above forms, the scores for each attribute together with frequency, severity and/or interference will be presented descriptively using summary statistics at each assessment time. Additionally, the worst severity and/or interference over the entire course will be summarized. The changes among main time points will be calculated. The results will be provided for the whole population and compared between subpopulations by arms and by age groups. Regression models based on longitudinal measurements can be constructed by considering the following covariates besides age groups: baseline demographics, clinical risk factors, and study arms. |
Assessed up to 12 years from last enrollment
|
|
Patient-reported fatigue
Zeitfenster: Baseline up to 1 year from end of study treatment
|
Will be measured by validated short forms from the Patient Reported Outcomes Measurement Information System initiatives. Domain scores will be converted to T-scores with an established standard deviation of 10 points with an average score normalized to 50 within the healthy adult population. The minimal clinically important difference (MCID) in these PRO measures has been accepted to be 2-3 points of the standard deviation (SD = 10) of the measure. To account for the dual primary PRO outcomes of fatigue and cognitive deficits, we will consider Bonferroni correction of p-values. Primary interests will be differences in T-scores between IO and chemotherapy arms at 1-year post completion of therapy. |
Baseline up to 1 year from end of study treatment
|
|
Patient-reported cognitive deficits
Zeitfenster: Baseline up to 1 year from end of study treatment
|
Will be measured by validated short forms from the Neuro-QoL initiative. Domain scores will be converted to T-scores with an established standard deviation of 10 points with an average score normalized to 50 within the healthy adult population. The MCID in these PRO measures has been accepted to be 2-3 points of the standard deviation (SD = 10) of the measure. To account for the dual primary PRO outcomes of fatigue and cognitive deficits, we will consider Bonferroni correction of p-values. Primary interests will be differences in T-scores between IO and chemotherapy arms at 1-year post completion of therapy. |
Baseline up to 1 year from end of study treatment
|
|
Patient-reported health-related quality of life
Zeitfenster: Baseline up to 1 year from end of study treatment
|
Domain scores will be converted to T-scores with an established standard deviation of 10 points with an average score normalized to 50 within the healthy adult population. The MCID in these PRO measures has been accepted to be 2-3 points of the standard deviation (SD = 10) of the measure. To account for the dual primary PRO outcomes of fatigue and cognitive deficits, we will consider Bonferroni correction of p-values. Primary interests will be differences in T-scores between IO and chemotherapy arms at 1-year post completion of therapy. |
Baseline up to 1 year from end of study treatment
|
|
Incidence of self-reported late morbidities
Zeitfenster: Assessed up to 12 years from last enrollment
|
Will be collected by using validated measures from the St. Jude Life Cohort. The cumulative incidence of late-morbidities (e.g., cardiovascular, pulmonary and endocrine) will be compared between the standard chemotherapy and the IO therapy and among different age groups (7-14; 15-40 and 41-60) with K-sample method. The frequencies of selected organ toxicities will be compared between two treatment arms, among the three age groups and between RT and non-RT with chi-square tests. |
Assessed up to 12 years from last enrollment
|
|
Effect of metabolic tumor burden (MTV) on PFS
Zeitfenster: At baseline prior to initiation of therapy
|
MTV will be measured at baseline using fludeoxyglucose F-18 (FDG)-PET. The Kaplan-Meier curves of PFS will be compared between the two levels with log-rank tests. |
At baseline prior to initiation of therapy
|
|
Effect of total lesion glycolysis (TLG) on PFS
Zeitfenster: At baseline prior to initiation of therapy
|
TLG will be measured at baseline using FDG-PET. The Kaplan-Meier curves of PFS will be compared between the two levels with log-rank tests. |
At baseline prior to initiation of therapy
|
|
Contribution of social determinants of health (SDOH) to PET2 response by race and ethnicity
Zeitfenster: After Cycle 2 of treatment (1 cycle = 28 days)
|
PET2 Response will be compared by race and ethnicity using Fisher exact tests. |
After Cycle 2 of treatment (1 cycle = 28 days)
|
|
Contribution of SDOH to PFS by race and ethnicity
Zeitfenster: Assessed up to 12 years after last enrollment
|
Kaplan-Meier (K-M) curves of PFS will be generated by racial/ethnic groups (e.g., non-Hispanic white [NHW], non-Hispanic black [NHB], Hispanic). The p values for the K-M curve comparison will be obtained from log-rank tests. Associations between race/ethnicity and PFS will be evaluated with univariable and multivariable Cox proportional hazard models by considering other covariates such as baseline clinical conditions, toxicities, SDOH, and treatment arm (standard vs. IO). Backward selection will be used to select those factors with p-value < 0.2, which will be included in final multivariable models. |
Assessed up to 12 years after last enrollment
|
|
Contribution of SDOH to OS by race and ethnicity
Zeitfenster: Assessed up to 12 years after last enrollment
|
K-M curves of OS will be generated by racial/ethnic groups (e.g., NHW, NHB, Hispanic). The p values for the K-M curve comparison will be obtained from log-rank tests. Associations between race/ethnicity and OS will be evaluated with univariable and multivariable Cox proportional hazard models by considering other covariates such as baseline clinical conditions, toxicities, SDOH, and treatment arm (standard vs. IO). Backward selection will be used to select those factors with p-value < 0.2, which will be included in final multivariable models. |
Assessed up to 12 years after last enrollment
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
PFS comparison between treatment arms for each age group
Zeitfenster: Up to 12 years
|
Will be compared between a standard chemotherapy approach and an IO therapy approach within different age groups (ages 5-11 years, 12-21 years, 22-39 years, 40-60 years) using log-rank tests. Cox regression models will be constructed to evaluate the treatment effects for different age groups while considering the impact of other potentially prognostic variables including baseline demographics and clinical risk factors. PFS and corresponding confidence intervals for each age group will be estimated with the Kaplan-Meier method, overall and by treatment arms. In additional models, age may be evaluated as a continuous variable with potentially non-linear effects on PFS. |
Up to 12 years
|
|
Concordance and discordance of 5-point score (PS) visual PET assessments
Zeitfenster: At baseline, post cycle 2, and at end of systemic therapy
|
The concordance and discordance of 5-PS visual PET assessment from rapid central review and local institutional review will be evaluated at each of the timepoints. Will collect and retrospectively review local vs. central review concordance rates. For discordant cases, will document the differences in treatments if only local review or only central review were performed |
At baseline, post cycle 2, and at end of systemic therapy
|
|
Association between FDG PET parameters obtained by automated measurements and PFS
Zeitfenster: At baseline, post cycle 2, and at the end of therapy
|
The association between FDG PET parameters obtained by automated measurements using convolutional neural networks and PFS will be evaluated in this aim. The PET parameters of interest are total MTV and TLG, tumor standardized uptake value change. PET parameters will be obtained based on artificial intelligence (AI) based measurements. The effect of these PET measurements will be evaluated by Cox regression models. |
At baseline, post cycle 2, and at the end of therapy
|
|
Agreement between AI derived FDG-PET measurement extraction and physician-based manual quantitative PET measurement
Zeitfenster: At baseline, post cycle 2, and at the end of therapy
|
Will compare AI derived automated quantitative FDG-PET measurement extraction and physician-based manual quantitative PET measurement with Spearman rank correlation coefficients for each extracted PET metric. |
At baseline, post cycle 2, and at the end of therapy
|
|
Incidence of patient reported adverse events and provider adverse event reporting
Zeitfenster: Assessed up to 12 years
|
Will be collected by PRO-CTCAE and Ped-PRO-CTCAE. The patient reported AEs will be compared to provider reported AEs reported descriptively. |
Assessed up to 12 years
|
|
Association between self-reported race/ethnicity and dimensional SDOH
Zeitfenster: Assessed up to 12 years
|
Will be evaluated by Chi-square tests or Fisher exact tests for sparse data. Will also calculate the area deprivation index (derived from patient-reported address and zip code to census block-group data for patients treated in the United States, and the Canadian Index of Multiple Deprivation for patients treated in Canada) and investigate its association with race/ethnicity and SDOH. |
Assessed up to 12 years
|
|
Post-relapse/post-progression OS by race/ethnicity and select SDOH measures
Zeitfenster: Assessed up to 12 years
|
The K-M curves will be presented together with p-values via log-rank tests across the different race/ethnicity groups for each treatment arm. Cox proportional hazard models to evaluate the relationship between race/ethnicity and post-relapse OS will be constructed. |
Assessed up to 12 years
|
|
Completion rate of PRO and health-related quality of life contact forms
Zeitfenster: At 1 year off treatment
|
Will be evaluated for the first 450 eligible participants. |
At 1 year off treatment
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Kara M Kelly, Roswell Park Cancer Institute
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Peptide
- Aminosäuren, Peptide und Proteine
- Oligopeptide
- Proteine
- Organische Chemikalien
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Untersuchungstechniken
- Klinische Labortechniken
- Diagnosetechniken und Verfahren
- Diagnose
- Azolen
- Kohlenwasserstoffe
- Kohlenwasserstoffe, zyklisch
- Kohlenhydrate
- Carboxylsäuren
- Alkaloide
- Podophyllotoxin
- Tetrahydronaphthalene
- Naphthenes
- Polycyclische aromatische Kohlenwasserstoffe
- Kohlenwasserstoffe, aromatisch
- Polycyclische Verbindungen
- Glucoside
- Glykoside
- Triazenes
- Imidazoles
- Amides
- Indolen
- Antikörper, monoklonal, humanisiert
- Antikörper, monoklonal
- Antikörper
- Immunglobuline
- Immunoproteine
- Blutproteine
- Serumglobuline
- Globuline
- Schwangerschaft
- Schwangerschaft
- Steroide
- Fusions-Ring-Verbindungen
- Benzolderivate
- Chemie -Techniken, analytisch
- Spektrumanalyse
- Phosphoramid -Senf
- Stickstoffsenfverbindungen
- Senfverbindungen
- Kohlenwasserstoffe, halogeniert
- Phosphoramide
- Organophosphorverbindungen
- Schwangerschaften
- Schwangerschaften
- Vinca -Alkaloide
- Secologanin Tryptaminalkaloide
- Indolalkaloide
- Indolizidine
- Indoliziner
- Anthracyclines
- Naphthatene
- Aminoglykoside
- Glykoconjugate
- Desoxyglucose
- Desoxyzucker
- Daunorubicin
- Säuren, carbocyclisch
- Glycopeptide
- Benzoates
- Benzamide
- Nivolumab
- Brentuximab Vedotin
- Fluordesoxyglucose F18
- Prednison
- Prednisolon
- Cyclophosphamid
- Etoposid
- Doxorubicin
- Vincristin
- Dacarbazin
- Methylprednisolon
- Vinblastin
- Bleomycin
- Procarbazin
- Handhabung von Proben
- Magnetresonanzspektroskopie
- Deltacortene
- Prednyliden
- Etoposidphosphat
Andere Studien-ID-Nummern
- NCI-2022-10845
- U10CA180886 (US NIH Stipendium/Vertrag)
- NCI-2022-10845 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- AHOD2131 (Andere Kennung: CTEP)
- AHOD2131 (Andere Kennung: Children's Oncology Group)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .